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Molecular switch systems that activate gene expression by a small molecule are 
effective technologies that are widely used in applied biological research. Previously, two 
orthogonal ligand receptor pairs (OLRP) were developed as potential molecular switch 
systems by modifying nuclear receptors, ligand-activated transcription factors, to bind 
and activate gene expression with the synthetic ligand LG335 and not with the natural 
ligand 9-cis retinoic acid (9cRA). The two OLRP previously discovered were RXR 
variant 130 (I268A, I310A, F313A, and L436F) (also known as GR130) and the RXR 
variant QCIMFI (Q275C, I310M, and F313I) and (also known as GRQCIMFI).   
The OLRP were further developed into molecular switches to provide controlled gene 
expression and potentially benefit gene therapy applications by replacing the DNA 
binding domain (DBD) with a Gal4 DBD, a yeast transcription factor. Both molecular 
switches are able to bind Gal4 RE in response to LG335 and activate expression of a 
luciferase or GFP reporter gene in either a two- or one-component system. When 
characterizing the GR130 variant in the two-component system, no activation was 
observed with the natural ligand 9cRA, and the variant displayed a 19±5-fold activation 
and a 50 nM EC50 value in the presence of LG335. When the GRQCIMFI variant was 
evaluated in the two-component system, activation was observed in the presence of 
LG335 with a 10 nM EC50 value and a 6±2-fold induction, and 9cRA induced activation 
only at the highest concentration. The GRQCIMFI variant was also characterized with 
the one-component system containing the reporter gene GFP in a transient transfection as 
 
 xx 
well as through retroviral transduction, displaying green fluorescence in 30% of the cells 
in the presence of 10 µM LG335. 
Several attempts were made to improve the molecular switch system. The VP16 
activation domain was fused to GRQCIMFI in an effort to increase the fold induction; 
however, the addition of the VP16 created a constitutively active protein. Another 
approach to improve the molecular switch incorporated error-prone PCR and the 
discovery of a variant, Q275C, I310M, F313I, L455M (QCIMFILM), which displayed a 
10-fold increase in sensitivity towards LG335 with a 5 nM EC50 value. Examination of 
the L455 position in the crystal structure of RXR revealed this residue is located outside 
of the ligand binding pocket on helix 12 (H12), but is able to significantly enhance 
receptor function. In fact, the single variant, L455M, was able to enhance receptor 
activation, compensate for a nonfunctional variant, as well as influence coactivator 
association.  
The long-term goal of this research is to develop a gene regulation system that would 
be used in human gene therapy trials. In the process of creating this system a deeper 
assessment of the nuclear receptor structure and function is made, which can be used for 






1.1 Introduction to Nuclear Receptors 
Nuclear receptors (NR) are a superfamily of proteins that have the ability to bind 
ligands and regulate transcription [1-3]. When a small molecule binds to a NR, a 
conformational change occurs in the receptor’s structure allowing recruitment of the 
transcription machinery. This role in transcription makes NR crucial for the induction of 
gene expression and regulation of a variety of cellular processes, such as proliferation, 
differentiation, intracellular signalling, reproduction, and metabolism [3-5].  
The sequencing of the human genome has lead to the identification of 48 human 
nuclear receptors [4, 6, 7]. This family is further divided into three sub-groups based on 
physiological ligands [8, 9]. The first class of receptors are called the endocrine receptors, 
binding hormones and vitamins. Examples of these receptors include the estrogen 
receptor (ER) and the vitamin D receptor (VDR), which are activated by 17β-estradiol 
and 1α, 25-dihydroxy vitamin D3, respectively [10, 11]. The adopted orphan NR are 
another class, and were identified based on sequence homology, but lacked a natural 
occurring ligand. However, their status was changed to “adopted” once the ligand for 
these receptors was identified. Examples in this class include the retinoid X receptor 
(RXR) and the pregnane X receptor (PXR), which bind phytanic acids and xenobiotics, 
respectively [12, 13]. “True” orphan receptors, the final subfamily, currently do not 
possess a natural or synthetic ligand. Examples of this class include short heterodimer 
partner (SHP) and tailless homolog (TLX). 
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Nuclear receptors have been implicated in various diseases including cancer, 
diabetes, obesity, and Parkinson’s disease. Due to their role in these diseases, researchers 
are vastly interested in studying nuclear receptor pathways, as well as, discovering drug 
therapies for NR-based diseases [9, 14-16]. In fact, many nuclear receptors are significant 
drug targets: 10-20% of drugs currently on the market are nuclear receptors ligands [4, 
17]. Examples of these drugs include tamoxifen, an anticancer drug targeting the estrogen 
receptor (ER) [18, 19], and bexarotene (Targretin®), a ligand that binds the retinoid X 
receptor (RXR) and is used to treat skin cancer [20, 21]. In attempt to discover potential 
new drug targets for NR, much focus has been put forth on understanding the structure 
and function of these proteins. 
1.2 Nuclear Receptor Structure 
As shown in Figure 1.1, most nuclear receptors consist of five main domains. The 
first domain is the A/B domain, containing the transcriptional activation function 1 (AF-
1). This domain is not well conserved, and varies in length within the nuclear receptor 
family [22]. However, this domain is known to interact with transcription factors, and 
undergoes post-translational modifications, such as phosphorylation, to enhance the 
signalling of transcription [8, 23-29]. 
The C domain or the DNA binding domain (DBD) is highly conserved among the 
NR family and is responsible for binding specific DNA sequences called response 
elements (RE). Structurally, the DBD has two α-helices packed together in a 
perpendicular fashion, shown in green in Figure 1.1. Within the DBD are two zinc finger 
motifs, composed of four cysteine residues forming a tetrahedral arrangement 







Figure 1.1: Nuclear Receptor Structure: Schematic illustration of nuclear receptor 










elements, the recognition helix of the DBD, residues 19-30, must insert itself into the 
major groove of the DNA. Therefore, this helix is important for allowing the receptor to 
bind alternate response elements [31].  
The D domain, which is composed of a flexible hinge region, connects the DBD 
to the ligand binding domain (LBD). The hinge region is not well conserved within the 
nuclear receptor family; however, this region allows the DBD and the LBD to have the 
flexibility to adopt different confirmations without steric hindrance [8].  
The ligand binding domain (LBD) or the E domain, shown in blue in Figure 1.1, 
has several components, and is responsible for the binding of small lipophilic molecules. 
Most nuclear receptors consist of an overall composition of 12 α-helices and a short β-
turn arranged in three layers to form an antiparallel “α-helical sandwich” [32-34]. One 
key feature of this domain is the activation function 2 (AF-2), also known as helix 12 
(H12). The conformational flexibility of AF-2 is essential for NR function and is also 
crucial for coregulator interaction [8, 33, 35]. The LBD also contains the strong 
dimerization interface. The majority of residues encompassed in this interface are located 
in helices 9 and 10 [36, 37].   
Divergence within the LBD is primarily seen in the shape and in residues forming 
the ligand binding pocket (LBP). The size of the pocket varies from no space for 
constitutively active receptors, such as the nuclear receptor related 1 (Nurr1), to receptors 
like steroidogenic factor 1 (SF-1), which has a pocket size of about 1600 Å [38, 39]. 
Other receptors have a LBP that can accommodate a variety of molecules, such as 
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cholesterol derivatives and large macrolides [40]. The location of the LBP is usually 
between helices 3, 7, 10, and the β-turn, and is lined with hydrophobic residues and a few 
hydrophilic residues at the deep ends of the pocket [8, 41]. The hydrophilic residues at 
the deep ends of the pocket anchor the ligand into place, while the hydrophobic residues 
determine the pocket size and shape [32]. 
Previously, solved crystal structures of nuclear receptors have provided insight 
into the structure, but lacked information on how different domains interact with each 
other, as well as, with other transcription factors. Recently, the crystal structure of the 
heterodimer PPARγ and RXRα and their corresponding ligands rosiglitazone and 9cRA, 
respectively, was published (PDB file 3DZU) (Figure 1.2). The domains were bound to 
the PPAR response element (DR1) and associated with two coactivator peptides [42]. 
Structural information obtained from this complex is consistent with previously solved 
structures; however, new details revealed insight into the nuclear receptor complex, 
previously unknown. For example, the DBD was known to interact with the DNA, but 
this study provided insight that the DBD interacts with the LBD as well. The hinge 
region, previously not crystallized, is significantly organized in the PPAR structure, and 
able to interact with the DNA, as well as the DBD of RXR. The A/B domain could not be 
visualized, leading to the hypothesis that this region lacks a folded motif [32, 42]. The 
value in understanding the structure of these complexes is important for gaining 
knowledge on the physiology of these receptors, which has implications in understanding 
NR-based diseases and impacts the design of new drug targets for these receptors. 












Figure 1.2: Structure of Nuclear Receptor Complex: Peroxisome proliferated-activated 
receptor (PPAR) (green) and the heterodimerization partner retinoid X receptor (RXR) 




Most NR function as homo- or heterodimers, which increases the binding efficiency 
to various DNA sequences called response elements (RE) [30, 43]. RE can be classified 
according to the receptor’s dimerization partner [8, 30]. For instance, steroid receptors 
bind to RE containing palindromic repeats of hexameric half site sequences [31, 44, 45], 
while RXR homo- and heterodimers bind to direct repeat sequences (5’-AGGTCA-3’). 
The direct repeat sequences are separated by one to five base-pair inter-half site spacing 
(DR-1-DR-5) [30, 46, 47]. Previous research has shown that the spacing between the half 
cites is crucial for the DBD to recognize the proper DNA sequence [43, 48]. 
As transcription factors, nuclear receptors are involved in activating the transcription 
process, which is controlled by the binding of a specific small molecule or ligand. When 
a ligand binds to the receptor, a conformational change occurs, transforming the receptor 
to the active conformation. NR ligands can be classified into several groups: agonists, 
antagonists, and selective nuclear receptor modulators (SNRMs) [1]. Ligands able to bind 
and activate the receptor, initiating the transcription process, are called agonists. Ligands 
that are able to bind without activating the receptor are called antagonists. The last class 
of ligands, SNRMs, have both agonistic and antagonistic characteristics [49]. 
Nuclear receptors can repress transcription by recruiting corepressors in the absence 
of a ligand, or in the presence of antagonist [50-53]. Corepressors are complexes of 
proteins known to silence genes by recruiting or possessing enzymatic activity, such as 
histone deacetylases (HDAC). These enzymes deacetylate the histone, allowing the DNA 
backbone to tightly wrap around the histones, denying access to the RNA polymerase 
(Figure 1.3). Corepressors such as N-CoR (nuclear receptor corepressor) and SMRT 
(silence mediator of retinoic acid and thyroid receptor) bind to the nuclear receptor 
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through a LXX[I/H]IXX[I/L] motifs (L represents leucine, X represents any amino acid, I 
represents isoleucine, and H represents histidine) also known as CoR-NR boxes [4, 49, 
54, 55].  
Figure 1.4 depicts the differences in the NR structure in the process of ligand binding 
and activating the receptor. The crystal structure of RXR LBD in the absence of ligand 
(apo-crystal structure) shows the C-terminal helix extended away from the core of the 
protein and exposed to the solvent [56]. The RXR crystal structure in the presence of 
ligand (holo-crystal structure) shows H12 positioned in a confirmation sealing the ligand 
binding pocket [57]. The positioning of H12 is critical in recruiting the CoAc complex, 
composed of several proteins such as histone acetyltransferase (HAT), kinase, and 
ATPase, which interact with the receptor and remodels the chromatin [58, 59]. 
Acetylation of the histones causes the DNA to unwind, allowing the RNA polymerase 
complex to access the DNA and initiate transcription (Figure 1.3). Previously, analysis of 
NR/coactivator interaction has shown that coactivators interact with NR through distinct 
LXXLL motifs (L represents leucine and X represents any amino acid). These motifs, 
present in the CoAc, serve as the interaction surface between the receptor and the CoAc 
[60].  
1.4 Retinoid X Receptor (RXR) 
RXR is a 463-residue protein that belongs to the class of retinoid receptors [61], 
and plays important roles in cellular morphogenesis and differentiation [62, 63]. There 
are three different isotypes and several isoforms of this receptor: RXRα (α1 and α2), β 
(β1 and β2), and γ (γ1 and γ2) [12]. RXRα and γ are tissue specific. RXRα is expressed in 




















Figure 1.3: Nuclear Receptor Function: (A) In the absence of ligand, the corepressor 
complex associates with NR, which deacetylate the histones, wrapping the DNA tightly 
around the histones. (B) In the presence of ligand, the coactivator complex associates 












Figure 1.4: Apo-Structure versus Holo-Structure: Schematic illustration of the 
conformational change of nuclear receptor upon ligand binding, and overlay of apo- 
(teal) and holo- (blue) structures. Helix 12 is visualized in purple and the ligand is 




in the muscle, brain, and pituitary gland [64-67]. On the other hand, RXRβ is 
ubiquitously expressed. Ligands for this receptor are various endogenous small lipophilic 
compounds, such as 9-cis-retinoic acid (9cRA), docosahexanoic acid, as well as the 
synthetic ligand bexarotene (Figure 1.5) [64, 68-71]. The most potent ligand for RXR is 
9cRA, with an EC50 value of 1.7 nM [72]. However, studies have suggested that 9cRA is 
not the natural ligand for RXR [73, 74]. Other molecules, such as the unsaturated fatty 
acids docosahexaenoic acid (DHA) and linoleic acid found in animal tissues close to the 
EC50 concentration are thought to be the “natural” ligand for this receptor [75]. 
Crystal structures of RXR bound to numerous ligands have provided considerable 
insight into the structure of this receptor. The crystal structure of RXR with 9cRA (Figure 
1.6) reveals a hydrophobic ligand binding pocket formed by residues located on helices 
H3, H5, H7, H11, and the β-turn [57]. These residues are well conserved in all RXR 
isotypes, indicating the lack of an existing isotype-specific ligand for RXR. H11 plays a 
crucial role in both the apo and holo conformations. In the absence of ligand, H11 lines 
the pocket with hydrophobic residues [57]; however, upon binding of ligand, H3 
displaces H11, permitting the helix to rotate 180
o
 and generating adequate space for 
ligand binding, as well as, stabilizing H12 [57]. 
One of RXR’s main functions is to serve as a heterodimerization partner for other 
nuclear receptors [43]. Most researchers classify the RXR dimerization partners as 
permissive and nonpermissive [15, 76, 77]. Permissive partners can activate transcription 
by the agonist of RXR and the partner nuclear receptor independently or together for an 























 Figure 1.6: RXR ligand binding pocket: The ligand, 9cRA, is shown in green and the residues 




(PXR), the PPAR, and the liver X receptor (LXR). Nonpermissive partners are not 
activated by a RXR agonist [12, 78]. Members of this group include the thyroid receptor 
(TR) and the vitamin D receptor (VDR). Shulman et al further defined RXR as acting as 
a “conditional permissive” heterodimerization partner [79]. Conditional permissive 
partners are activated by the ligand of the partner in the pair, but the RXR ligand is 
required for full activation. RXR is not only found in dimers; this receptor can self-
associate into a tetramer complex in the absence of ligand; possibly the transcriptionally 
silent form of this receptor since it cannot interact with other receptors or coregulators 
[80-82]. 
In summary, nuclear receptors are involved in many metabolic processes, and as a 
result they are implicated in many diseases, ranging from diabetes to Parkinson’s disease. 
Much interest and research is put forth towards discovering drugs that target these 
receptors. Gaining insight into the structure and function of nuclear receptors allows 
pharmaceutical companies to develop novel agonists, antagonists, and SNRMs to treat 
NR-based diseases.  In addition, nuclear receptors can also be used for applications such 
as protein engineering and gene therapy [83]. This work presented in this dissertation 
focuses on engineering RXR for controlling gene expression in mammalian cell culture 
for future use in gene therapy applications. 
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GENE THERAPY AND MOLECULAR SWITCH SYSTEMS 
 
2.1 Gene Therapy 
Gene therapy is the use of DNA as a drug to treat genetic disorders, as well as other 
diseases by replacing a defective gene(s) with a normal gene(s) [1-3]. The fundamentals 
of gene therapy show great promise and is a highly pursued research area due to the 
frequency of human diseases based on genetic or inherited defects [4]. Severe combined 
immunodeficiency (SCID) disorders are a primary target of gene therapy applications. 
These disorders usually have a characteristic defect in both the T and B-lymphocyte 
systems, which results in an onset of serious infections [5, 6]. One of the first successful 
gene therapy trials took place about twenty years ago, involving the transfer of an 
adenosine deaminase (ADA) gene into the lymphocytes of a patient with the defective 
enzyme [7, 8]. This clinical trial treated 18 patients and 17 of them benefited from this 
life-saving technology. Since then over 1300 gene therapy clinical trials have been 
conducted [9]. One of the many success stories includes the gene therapy trial in 2007, 
involving a retinal disease caused by a mutation in the RPE65 gene. This gene encodes 
for an enzyme that converts all trans retinyl ester to 11-cis retinal, a natural ligand for G 
protein-coupled receptors in photoreceptor cells [10-12]. A recombinant adeno-associated 
virus was used to safely deliver the RPE65 gene for long-term restoration of vision [10, 
13, 14]. 
Despite the appeal of gene therapy in treating patients, the failures of this method 
have posed several safety and ethical issues. For example, several years after the clinical 
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trials were conducted for the treatment of the X linked form of SCID (XSCID), cases of 
leukemia developed in five of the twenty subjected treated [5]. XSCID is an inherited 
defected in a gene that encodes a mutation in a common cytokine needed for lymphocyte 
development and function [5, 6]. Another setback of gene therapy occurred in 1999 with 
the death of 18-year-old Jesse Gelsinger, a patient who passed away due to a severe 
immune response from treatment with large amounts of adenoviral particles [15]. 
Although there are numerous advantages of gene therapy, these failed attempts have 
affected the progression of this promising technology. 
2.1.1 Gene Delivery Methods 
In order to treat these diseases, genetic material must be delivered to target cells or 
tissue. Currently, two methods, nonviral and viral, have been developed to deliver DNA 
to cells or tissue. Examples of nonviral methods include DNA electroporation, which 
involves delivering a high-voltage electric pulse to the cell, allowing DNA diffusion 
through the cell membrane [16-18]. Another common example of a nonviral method is 
the use of cationic lipids, which condenses and encapsulates the DNA into a liposome, 
also known as a lipoplex [19].  As shown in Figure 2.1, cationic lipids are polymers with 
positively charged heads that can directly interact with the DNA backbone [20], and 
hydrophobic tails. X-ray diffraction studies have revealed insight into the three 
dimensional structure of these complexes. These studies have revealed that a lipoplex can 
arrange in two structures: a “DNA sandwich” where the DNA is packed inside 
monolayers formed by the cationic lipid or a “honeycomb” structure where the DNA is 
encapsulated in monolayer tubes that form a hexagonal shape [21]. These lipoplexes can 
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enter the cell via nonspecific endocystosis [22], and this technique is used quite often in 
transient transfections, as well as in clinical trials [23-27].  
Common viral methods used for gene therapy include the retroviral, adenoviral, and 
adeno-associated viral (AAV) delivery systems [28]. Viruses are infectious agents or 
pathogens that cause disease to its host [29]. However, new DNA delivery methods have 
been engineered based on the fundamentals of the function of viruses, and have been 
used in several gene therapy applications. The viral systems that will be discussed in this 
chapter have been modified to infect a host; however, the pathogenesis of these viruses 
that cause the virus to replicate and cause damage to the host have been excluded [22]. 
Retroviruses are RNA viruses that can integrate genetic material into the genome of a 
host, allowing transcription of the therapeutic gene to take place. Figure 2.2 shows the 
mechanism of the virus’ entry to the cell via receptor-mediated endoctyosis. Once the 
virus enters the cell, the RNA is released and transcribed into double stranded DNA by 
the reverse transcriptase. Finally, the DNA enters the nucleus, integrates into the host 
genome, and enabling the expression of viral proteins. Adenoviruses are double-stranded 
DNA viruses that remain episomal in the nucleus but exploit the host’s nuclear 
machinery to facilitate gene expression. Adeno-associated viruses (AAV) are single-
stranded DNA viruses that integrate genetic material into the genome of the host; 
however, the virus remains inactivate or in the latent stage until a subsequent virus infects 
the host [19].  
2.1.2 Gene Therapy Challenges 
Numerous challenges need to be overcome before gene therapy can be implemented 








Figure 2.1: Mechanism for Cationic Lipids: DNA can supercoil and form a complex 
with the cationic lipids. The lipoplex then enters into the cell through endocystosis where 









Figure 2.2: Mechanism of action for retroviruses: The virion enters the cell through 
receptor-mediated endocytosis. The RNA and virion proteins are releases into the cell 
where reverse transcription takes place. Finally, the DNA enters the nucleus and 




section above has been one of the challenges with this area of research. Viruses have 
been the choice of most gene therapy studies. However, each viral delivery system has 
advantages and limitations depending on the type of tissue or cells targeted and the 
duration of expression of the therapeutic gene. For example, retroviruses are able to 
transfer genetic material efficiently and allow long-term expression of the therapeutic 
gene. However, the lack of control of gene integration site has caused leukemia in various 
XSCID case studies [30].   
Another challenge in gene therapy is the short-lived gene expression, which 
introduces the problem of retention of exogenous genes or the silencing of gene 
expression over an extended period of time. For example, nonviral methods are known to 
transfer genes inefficiently [31], causing inefficient gene expression. Therefore, this 
method is not ideal when treating certain diseases, such as primary immune deficiency 
disorders, that require long-term gene expression.  
Immunogenic responses, another challenge of gene therapy, can be induced by 
introducing a foreign object into a host. All gene therapy methods have the potential of 
inducing an immunogenic response, reducing the effectiveness of gene therapy, as well as 
causing severe illnesses. This challenge is a main disadvantage of the adenovirus delivery 
system, since acute and chronic immune responses have been observed in several animal 
model studies [32].  
Finally, the lack of transcriptional control of the therapeutic gene is another problem 
faced within this area of research. Most endogenous genes are turned on or off by the 
addition or removal of a specific signal that causes a cascade of proteins to initiate the 
transcription process. When a foreign gene is introduced into cells, the expression of that 
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gene is primarily controlled by the promoter region that recruits the transcription 
machinery, which in many cases instantly induces gene expression. However, if the 
therapeutic gene is overexpressed, then other complications, as well as other diseases 
within the host may occur. Therefore, there is a need to develop new regulation systems 
to control expression of the therapeutic gene.  
Bone marrow transplantation has been a beneficial treatment to treating patients with 
inherited disorders such as SCID, since bone marrow contains hematopoietic stem cells 
(HSC) that are known to restore the immune response system [5, 6]. However the lack of 
donor matches and the frequency of transplantations have limited the benefits of this 
treatment. The repopulation of healthy HSC in vitro and in vivo would offer a novel 
treatment to permanently cure these life-threatening diseases. One potential target gene 
known to expand HSC count is the homeobox gene HOXB4 [33-35]; however, high 
expression of this gene impairs HSC differentiation. Hence the need to develop molecular 
switch systems that would provide the appropriate gene expression levels when needed 
by the administration of a drug, resulting in HSC repopulation that would restore an 
impaired immune response system. 
2.2 Criteria of a Molecular Switch System 
Gene regulation systems are important research tools for studying gene function 
and can provide numerous benefits for clinical applications. Several systems have been 
designed that place a target transgene under the control of an engineered transcription 
factor that is activated in the presence of an exogenous ligand [36]. These systems have 
been successfully used to control expression of a target transgene in a cellular 
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environment with high expression levels in response to an extensive range of ligand 
concentrations [37]. 
As a mechanism for controlling gene expression, several researchers have focused 
on the development of molecular switch systems. According to Toniatti and coworkers, 
there are several criteria for an effective molecular switch system. First, the switch should 
be an “ON-switch” and not an “OFF-switch”, meaning the switch should be able to be 
turned on and off based on the addition or removal of drug. “OFF-switches” have two 
drawbacks. One drawback is a prolonged exposure of drug to silence the gene, and the 
second is the rate of gene expression is determined by the drug clearance. The second 
criterion is the drug and the molecular switch should be target specific and not interfere 
with endogenous metabolic pathways. The potential drug should have appropriate 
pharmacological properties, which include a metabolism profile that is compatible with 
prolonged usage. Third, target gene expression should correlate with the dose of the 
ligand. The system should have low basal activity, be inactive in the absence of the 
ligand but strongly stimulated by ligand administration, hence high fold induction levels. 
Finally, the system should not induce an immune response in humans. [38].  
2.3 Current Molecular Switch Systems 
To date, several research groups have developed molecular switch systems to control 
transgene expression in both cell culture assays, as well as, animal models. Some of the 
most commonly used examples include the progesterone receptor (PR)/ mifepristone 
(RU486) inducible system (also known as GeneSwitch®), the tetracycline inducible 




The progesterone receptor (PR) inducible system regulates gene expression using 
RU486, a synthetic PR antagonist. This ligand binds to a chimeric regulator composed of 
a truncated PR fused to a Gal4 DNA binding domain, a yeast transcription factor, and the 
p65 activation domain [41-44], a human transcription factor involved in chromatin 
remodelling [45]. As shown in Figure 2.3, the regulator then binds a DNA sequence 
composed of six Gal4 response elements (RE) and activates gene expression. This system 
has been used in animal models, regulating human growth hormone (hGH) expression in 
the liver of mice using the adenoviral delivery system. One major disadvantage of the 
GeneSwitch® system is the usage of RU486, a female contraceptive drug used to induce 
abortion [46]. Long term usage of this drug could lead to significant side effects, making 
this system difficult for animal studies [47, 48]. 
The tetracycline (Tet) inducible system is based on the prokaryotic repressor 
protein (TetR) that binds to a specific DNA sequence called tetO. In the absence of 
tetracycline (Tet) or its derivative doxycycline (dox), the TetR proteins are tightly bound 
to the DNA sequence [49]. In the presence of ligand, the TetR is released from DNA and 
gene expression occurs [50]. Over the years, the TetR protein has been involved in many 
molecular switch systems. The first molecular switch system this protein was involved in 
had the TetR protein fused to the VP16 transactivator of the herpes simplex virus [39]. 
VP16 is a very strong transactivator and is known to have a strong interaction with the 
TATA-binding protein (TBP), TFIIB, and the Spt-Ada-Gcn5 (SAGA) histone 
acetyltransferase complex allowing transcription to occur more efficiently [51, 52]. This 
system can function as both an “ON-switch” as well as an “OFF-switch” [53]. The “OFF-









Figure 2.3: Schematic Diagram of Geneswitch®: The fusion protein composed of a 
Gal4 DBD, a mutant progesterone receptor LBD, and a p65 activation domain is 
constitutively expressed. Upon the addition of the ligand, RU486, the fusion protein can 











Figure 2.4: Schematic Diagram of Tetracycline Inducible System: OFF-Switch is 
composed of the TetR and VP16 fusion protein that is constitutively expressed. In the 
presence of ligand doxycycline (dox) represses gene expression and in the absence of 
ligand gene expression takes place. The OFF-Switch constitutively expressed the 
chimeric protein with a mutant TetR (rTetR) activates gene expression the presence of 




the absence of ligand (Figure 2.4). Upon the addition of ligand, tTA is released from the 
promoter region and gene expression is silenced. Four mutations in the TetR domain 
(rtTA) reversed the activity of this protein, only interacting with the tetO sequence in the 
presence of ligand, which created the “ON-switch” [52].  
An advantage of the Tet inducible system is that the ligand dox is inexpensive and 
“bioavailable” [54, 55]. This molecular switch system has also been used in several in 
vitro and in vivo models including rodents and monkeys, and has been delivered in 
various viral vectors including AAV, adenovirus, and lentivirus [47, 56]. However, one 
drawback of this system is the utilization of bacterial proteins, which may induce an 
immunogenic response in human gene therapy trials [57, 58].  
Finally, the ecdysone-responsive regulation system is based on a heterodimer 
between the insect steroid hormone receptor, ecdysone receptor (EcR), and the retinoid X 
receptor (RXR) (Figure 2.5) [59]. The ecdysone receptor is a nuclear receptor in insects, 
involved in molting and metamorphosis, and consists of the heterodimer partner 
ultraspirale (USP) [60-62]. In this system the DBD of EcR was altered to resemble the 
glucocorticoid receptor (GR), binding to a hybrid DNA sequence of the GR response 
elements (RE) and the EcR RE (EGRE). VP16 is fused to the RXR LBD; RXR serves as 
the human ortholog of USP [40]. The LBD of EcR carries a transcriptional silencer; 
therefore, the absence of ligand can recruit corepressors to silence gene expression [60]. 
Upon the addition of ecdysteriods, insect steroids that are structurally different than 
mammalian steroids, the EcR chimera heterodimerizes with RXR-VP16 and expression 
of target gene occurs. Despite low basal expression and high fold induction of this system 









Figure 2.5: Schematic Diagram of Rheoswitch®: Two fusion proteins are constitutively 
expressed: RXR fused the VP16 activation domain and a hybrid EcR and GR DBD fused 
to the EcR LBD. Upon the addition of ecodysteriods, both fusion protein are recruited to 




complicates viral delivery. Another disadvantage of this system is the overexpression of 
RXR poses a safety concern, since RXR plays a significant role in many metabolic 
pathways [62, 65-68].  
These three successful ligand-dependent molecular switch systems have been 
used for various cellular studies; however, these systems contain certain limitations for in 
vivo applications. The concerns posed by these systems permit the development of new or 
improved molecular switch systems. This thesis will describe a molecular switch system 
based on an engineered nuclear receptor and a synthetic small molecule. The 
characterization of this molecular switch system will be discussed in the following 
chapters and provide a new potential system for gene therapy applications. 
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CHARACTERIZATION OF A MOLECULAR SWITCH WITH THE 
GR130 VARIANT 
 
This chapter will discuss the characterization of the GR130 variant in a two- and 
one-component system. This work was performed with plasmids containing the GR130 
variant inherited from a previous Doyle lab member Priyanka Rohatgi; therefore, it was 
assumed that the plasmid contained the corrected variant [1]. However, when the variant 
was sequenced at the end of this study, it was found to be the GRQCIMFI variant. The 
data collected with the two- and one-component system that contained the luciferase 
reporter gene was resequenced and confirmed to be the GR130 variant. The data 
collected with the one-component system containing the GFP reporter gene, was not 
confirmed and is unclear if the GR130 or the GRQCIMFI variant was tested. 
3.1 Engineering RXR 
The first step in engineering a molecular switch system is to create an orthogonal 
ligand/receptor pair (OLRP). An OLRP consists of a modified protein designed to bind a 
new small molecule, and not possess the ability to bind its natural ligand [2]. Figure 3.1 
describes criteria for an OLRP in relation to the retinoid X receptor (RXR) and a 
synthetic compound structurally similar to an RXR agonist but that does not activate this 
receptor. As previously mentioned in Chapter 1, RXR can transcriptionally activate an 
endogenous gene with its natural ligand 9-cis retinoic acid (9cRA), but not the synthetic 
ligand LG335, an inactive analog of the FDA approved drug Targretin (Figure 3.1A) [3]. 
To develop an OLRP, RXR variants were created to bind the synthetic ligand, LG335. At 
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the same time, these variants should not activate transcription with the natural ligand, 
9cRA (Figure 3.1B). Thus the OLRP involves an engineered variant that binds and 
activates in response to a synthetic small molecule not present in mammalian cells and 
should not activate endogenous receptors. 
The compound LG335 was selected as the ligand target since previous studies 
showed the compound does not activate the wild-type receptor. The ligand was 
developed by the company Ligand Pharmaceuticals that was in pursuit of a selective 
RXR agonist [4, 5]. A series of compounds were synthesized included LG335 and the 
FDA approved drug Targretin. Targretin is a drug currently on the market used as a 
anticancer agent used in several therapies [6]. Doyle and coworkers previously 
discovered a RXR variant Q275C, I310M, F313I (QCIMFI) that was orthogonal to the 
ligand LG335 and will be characterized in Chapter 4; therefore, this ligand was chosen to 
engineer new OLRP [7]. 
Since nuclear receptors (NR) naturally contain DNA binding domains (DBD) that 
bind to NR response elements (RE), the OLRP in the molecular switch system must be 
further engineered so that interference with endogenous pathways is not observed. To 
address this issue, the DBD of RXR was replaced by the Gal4 DBD (Figure 3.1C). The 
Gal4 protein is a yeast transcription factor that activates transcription of genes involved 
in galactose catabolism, and is not present in mammalian cells [8-11]. The modularity of 
both nuclear receptors and the Gal4 protein allows their DBD to be switched. Thus, this 
new transcription factor will not bind to the RXR RE and activate endogenous genes, but 
will bind to an artificial promoter containing Gal4 RE and active transcription of a 





Figure 3.1: Engineering a Molecular Switch System: (A) 9cRA binds to RXRwt and 
activates expression of endogenous genes, and LG335 does not activate expression of 
endogenous genes. (B) RXR LBD was engineered to bind LG335 and activate gene 
expression, but not bind 9cRA. (C) RXR DBD was replaced with the Gal4 DBD that 
binds Gal4 RE. (D) RXRwt should not bind Gal4 RE and activate expression of 
therapeutic gene and the molecular switch should not bind RXR RE and activate 
expression of endogenous genes. 
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3.4.1 Previous Work 
Previously, Doyle et al and Schwimmer et al engineered RXR variants to bind 
and activate in response to the novel small molecule, LG335. The best candidate, variant 
130, obtained from a library of 3.2 x10
4
 variants displayed a 30 nM EC50 value with 
LG335 and no activation with 9cRA. This variant was determined to have four mutations: 
I268A, I310A, F313A, and L436F [12], and was chosen as a candidate for this molecular 
switch system and further characterized. 
In order to use this variant in a molecular switch system, the DBD of this variant 
was switched from a RXR DBD to a Gal4 DBD. The Gal4 DBD binds four multiple 
repeats of a 17-mer DNA sequence called Gal4 RE [13]. This sequence, unique to yeast, 
provides specificity to a target promoter region containing Gal4 RE, and should not bind 
to endogenous mammalian DNA sequences. Thus, the fusion of the Gal4 DBD and the 
LBD of the RXR variant 130 (GR130) creates a new transcription factor involved in this 
molecular switch system.  
Previously, GR130 was cloned into the retroviral vector pMSCV, creating a new 
plasmid, pMSCVGR130 [1]. This plasmid contains two long terminal repeat (LTR) 
regions. The 5’ LTR region is composed of enhancer elements and the promoter that 
allows GR130 to be constitutively expressed (Figure 3.2). Both LTRs and the Ψ region 
also possess retroviral signals. The second part of the molecular switch system is the 
reporter system. On a separate plasmid, the Gal4 RE located upstream from a minimal 
thymidine kinase promoter (Ptk) controls expression of the reporter gene, Renilla 













Figure 3.2: Schematic diagram of two-component switch system: The pMSCVGR130 
plasmid constitutively expresses GR130. Upon the addition of LG335, GR130 binds to 
four Gal4 RE upstream from a minimal thymidine kinase promoter controlling expression 
of the luciferase reporter gene. 
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This chapter will address the characterization of this molecular switch system 
through transient transfections in a two-component and one-component system. The 
difference between the two systems is that the two-component system involves two 
plasmids, whereas the one-component system only involves one plasmid. Lastly, stable 
expression of the one component system was also characterized using a retrovirus, as 
well as, transient transfection with a selection marker. 
3.2 GR130 in the Two-Component System 
As shown in Figure 3.2, the two component system is composed of two plasmids. 
The first plasmid, pMSCVGR130, is a retroviral vector that has two LTR regions, a Ψ 
region, and the GR130 gene. The 5’ LTR region allows GR130 to be constitutively 
expressed. Upon binding of LG335, GR130 binds to the reporter plasmid, p17*4TataLuc, 
containing four tandem Gal4 RE located upstream from a minimal thymidine kinase 
promoter (Ptk). The binding of GR130 to the promoter region induces expression of the 
Renilla luciferase gene. 
The molecular switch was first tested in a luciferase assay to determine the 
activity of the GR130 variant with LG335 and 9cRA. HEK293T cells, human embryonic 
kidney cells, were cotransfected with a 1:2 molar ratio of pMSCVGR130 and 
p17*4TataLuc using the transfection agent Lipofectamine 2000, a cationic lipid. As a 
positive control, the pCMXGRXRwt was transfected alongside. This plasmid contains 
the Gal4 DBD fused to RXRwt (GRXRwt), and the fusion protein is constitutively 
expressed under the control of the cytomegalovirus (CMV) promoter.  
The results in Figure 3.3 show that GR130 is not activated by 9cRA, but 
activation is observed in response to LG335, displaying a 19±5-fold induction and 50 nM 
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EC50 value, comparable to results found by Schwimmer et al [12]. The control, GRXRwt, 
showed activation with both LG335 and 9cRA. Maximal activation was observed at 1 
µM 9cRA (280 nM EC50 value) with a 9±1-fold induction, and maximal activation was 
observed at 3.2 µM LG335 (690 nM EC50 value) and a 5±1-fold induction. The activation 
of GRXRwt by the synthetic ligand is not of any concern since the fusion of the Gal4 
DBD and the RXRwt LBD does not exist in vivo. Therefore, the molecular switch system 
developed has the ability to regulate transgene expression upon the addition of ligand, 
and the receptor is orthogonal to the ligand LG335. 
3.3 Characterization of the One-Component Molecular Switch System 
The previous section shows the two-component system is capable of regulating gene 
expression. However, cotransfecting two plasmids are less desirable than transfecting a 
single plasmid due to the fact that introducing two plasmids decreases the transfection 
efficiency. To increase the versatility for stable expression in cell culture, the components 
in the p17*4TataLuc plasmid were cloned into the pMSCVGR130 vector, called 
pMSCVGR130Talu (Figure 3.4). In this vector, GR130 is constitutively expressed, as 
shown in Figure 3.4, and in the presence of LG335 will bind to the Gal4 RE located on 
the same plasmid and induces expression of the Renilla luciferase reporter gene. Another 
reporter, the enhanced green fluorescent protein (eGFP), was also tested in order to 
visualize protein expression.  
When GR130 was tested in the one-component system with the luciferase gene, as 
shown in Figure 3.5, reduced luciferase activity is observed, displaying a 2-fold increase 
in the EC50 value (100 nM) compared to the two component system (50 nM EC50 value). 














Figure 3.3: Activation Profile of G130 and GRXRwt: Activation profiles of GR130 and 

















Figure 3.4: Schematic diagram of one-component system: The pMSCVGR130GFP 
plasmid constitutively expressed GR130. Upon the addition of LG335, GR130 binds to 
the same plasmid containing Gal4 RE located upstream from a minimal thymidine kinase 
promoter controlling expression of the target gene, eGFP or luciferase.  
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GR130 variant was compared to the Q275C, I310M, F313I (GRQCIMFI) variant, 
previously developed by Doyle et al and also showed reverse ligand specificity with 
LG335. The GRQCIMFI variant shows a 6±1-fold induction and a 271 nM EC50 value in 
the one-component system. These results show the GRQCIMFI variant is able to induce 
activation, while the GR130 variant does not; therefore the GR130 variant needs further 
improvement if this variant will be used in the molecular switch system. 
Since a low fold induction was observed with the one-component system, the 
green fluorescent protein (GFP) was used to determine if the amount of activation 
provided sufficient gene expression to visualize GFP. The pMSCVGR130GFP plasmid, 
constitutively expresses GR130 and upon the addition of LG335, GR130 can bind to the 
same plasmid and induce expression of eGFP (Figure 3.4) [1]. After the 
pMSCVGR130GFP plasmid was transfected into HEK293T cells, cells were then treated 
with and without 10 µM LG335 eight hours after the transfection.  Fluorescent images of 
the cells were taken 48 hours after the transfection.  
To evaluate the fluorescent images, the percentage of fluorescent cells was 
determined by manually counting the number of the fluorescent cells and taking into 
account the total number of cells, multiplying by a factor of 100. As shown in Figure 3.6, 
very little background is seen when no ligand is added to the system; however, when 10 
µM LG335 is added, GFP expression is observed in approximately 30% of the cells. To 
evaluate transfection efficiency, these results were compared to a control plasmid 
pMSCVIRESGFP, which contains an internal ribosome entry site (IRES) and 
constitutively expresses eGFP (Figure 3.7). IRES is a DNA sequence that initiates 














Figure 3.5: Activation Profile in the One-Component System: Activation profile of the 
one-component system with GR130 (●) and GRQCIMFI (■) with LG335. 
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5’ end region, allowing the translation of protein to occur more efficiently [14, 15]. The 
transfection efficiency with the IRESGFP plasmid was observed to be approximately 
60%. Despite the low fold induction observed with the luciferase reporter gene, the 
molecular switch system is able to induce a reasonable amount of GFP expression in the 
one component system with the GR130 variant. 
In comparing the one-component and the two-component systems, both systems 
were able to regulate target gene expression proficiently; however, each system has 
advantages and disadvantages. The two-component system displays a high fold induction 
and a lower EC50 values, but the presence of two plasmids reduces transfection efficiency 
and is not desirable in gene therapy applications. The one-component system provides 
versatility by decreasing the amount of exogenous DNA required [16]; however, a 
decrease in gene expression is also observed when all components are combined into one 
plasmid. 
3.4 Stable Expression of the Molecular Switch System 
Since the potential molecular switch GR130 was able to turn on gene expression with 
the eGFP reporter. The next step was to characterize stable expression of the molecular 
switch system. Stable expression allows the components of the molecular switch system 
to be expressed in a cell over an extended period of time, which would be more favorable 
in gene therapy applications. In transient transfections, a two-fold problem exists. First, 
cationic lipids do not enter cells very efficiently because they are easily degraded [17]. 
Second, expression of target gene is lost over time, since cells do not retain plasmid. In 
this section, two types of methods will be used to characterize stable expression of the 
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Figure 3.6: Fluorescent Images of Transient Transfection with pMSCVGR130GFP: 
Fluorescent images of HEK293T cells transiently transfected with GR130GFP in the 
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Figure 3.7: Fluorescent Image of Transient Transfection with pMSCVIRESGFP: (A) 




integrate the DNA of the molecular switch system into the genome of the host. The 
second section will discuss using transient transfection and a selection marker. This 
method forces cells to retain the episomal DNA, since the same plasmid expresses an 
antibiotic resistant gene, allowing cells to survive in media treated with antibiotics. 
3.4.1 First Method: Retroviral transduction 
As previously discussed in Chapter 2, viral systems allow long-term expression of 
the therapeutic gene, and can enter cells very efficiently. Several viral systems exist; 
however, the retrovirus system was chosen for the molecular switch system. Retroviruses 
enter the cells and integrate DNA into the genome of the host. Retroviral infectious 
particles are created by transiently transfecting a retroviral plasmid into a packaging cell 
line (Figure 3.8). Packaging cell lines possess trans-elements, such as the gag, pol, and 
env genes [18]. These genes produce essential proteins such as reverse transcriptase, 
integrase, and viral envelope proteins that make retroviruses effective at entering cells 
and integrating genetic material into the genome of host [19].  The packaging cell line 
lacks the packaging and regulation signals, the cis-elements, which prevent mobilization 
of virion particles. Therefore, viral particles cannot be produced until the retroviral 
plasmid is transfected into the packaging cell line.  
As shown in Figure 3.8, the viral vector enters the nucleus and is transcribed into 
RNA. The packaging signal, Ψ, on the RNA sequence is recognized by the viral proteins, 
allowing the packaging of the virus. Lastly, the virions bud off the cell membrane, and 
retains the envelope and cell membrane proteins that allow the virus to infect a specific 
host [19]. The virus used for the molecular switch system is an ecotropic retrovirus, 
which specifically infects rodents, and was used for testing in a murine cell line.  
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To optimize the viral transduction, the control plasmid, pMSCVIRESGFP was 
used. This plasmid constitutively expresses eGFP and contains an internal ribosomal 
entry site (IRES) prior to the eGFP DNA sequence. EcoPack 2-293 cells were transfected 
with pMSCVIRESGFP using the transfection reagent, Lipofectamine 2000. Viral 
particles released in the media were collected every 12 hours for four to five days, and 
then transduced into NIH3T3 cells, mouse fibroblast cells. Previously, viral particles 
were shown to infect cells more efficiently when incubated with two charged polymers 
[20-22]; therefore, two polymers were used to transduce the virus.  
The first polymer, polybrene (PB), a positively charged polymer, is known to 
neutralize charges between virions and sugars on the cell surface [23, 24]. The second 
polymer, chrondroitin sulfate C (CSC), an anionic glycosaminoglycan, has been shown to 
increase viral mediated transfer [21, 25]. The optimal concentration of polymers was 
assessed by incubating viral stocks with a range of polymer concentrations (8-200 
µg/mL). The optimal protocol found for retroviral transductions was to first incubate with 
80 µg/mL of CSC for 10 minutes, and then incubate with 80 µg/mL of PB for 10 
minutes. The viral stock was then added to NIH3T3 cells with 8 µg/mL of PB. To further 
enhance this protocol, the stock solution composed of retroviral infectious particles was 
concentrated in an effort to increase the amount of viral particles that can infect cells. 
However, the concentrated stocks did not enhance the transduction efficiency. 
NIH3T3 cells transduced with the IRESGFP virus were analyzed using flow 
cytometry to measure the efficiency of the viral transduction. Flow cytometry is a 
technique used to analyzed thousands of cells or particles that are in liquid suspension 










Figure 3.8: Diagram of Packaging Cell Line: The retroviral vector is transiently 
transfected into the packaging cell line. The vector enters the nucleus where it is 
transcribed into RNA. The Ψ region on the RNA is recognized by the viral proteins 
expressed in the packaging cells line and is packaged into virions. The virions then bud 
from the cell retaining the envelope and cell membrane proteins. Collected from the 
media and transduced onto target cells. 
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characteristics as they pass through a laser [26-28]. Data collected from samples can be 
plotted on a histogram, which produces a graph displaying a single parameter on the x-
axis against the number of cells analyzed on the y-axis. A gate can be placed on the 
histogram that selects for a subpopulation of cells that exhibit a specific characteristic, 
which allows the percentage of cells displaying a specific characteristic to be determined.  
Figure 3.9 is a histogram, indicating the number of fluorescent cells in a given 
sample. Cells transduced with no virus, 10 µL of virus, and 100 µL of virus were 
subjected flow cytometry, analyzed, and plotted on a histogram. The negative control, 
cells not transduced with virus, were first analyzed by setting a gate above the fluorescent 
intensity of these cells, indicating autofluorescence. From this control, cell emitting a 
fluorescent intensity above autofluorescence can be evaluated and the percentage of GFP 
positive cell can be determined. When evaluating cells transduced with 10 µL of virus, 
GFP fluorescence was observed in 30% of the cells, and cells transduced with 100 µL of 
virus were 77% positive for GFP fluorescence (Figure 3.9).  
These results show a successful transduction in NIH3T3 cells with the IRESGFP 
retroviral particles. The optimal conditions to transduce cells were by incubating cells 
with the charged polymers CSC and PB, then adding 100 µL of the viral stock to NIH3T3 
cells. When cells were transduced with pMSCVGR130GFP, GFP fluorescence was 
barely observed; therefore, another route to evaluate stable expression of the molecular 



















Figure 3.9: Flow Cytometry Histograms of NIH3T3 cells transduced with 
pMSCVIRESGFP: Histogram displaying flow cytometry data of NIH3T3 cells 
transduced with no virus, 10 μL, or 100μL of IRESGFP. 
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3.4.2 Second Method: Stable Expression Using a Selection Marker 
 Despite the advantage of using viral methods for the introduction of the 
molecular switch system, a considerably low fluorescent intensity of GFP was observed 
in comparison to transient transfections. Therefore, characterization of stable expression 
of the molecular switch system was attempted by adding selective pressure to the 
transient transfection method using a plasmid that contained a selection marker. This 
method utilizes the power of genetic selection to maintain the gene of interest over a 
extend period of time. A selection marker in this case is an antibiotic resistance gene, the 
neomycin resistance gene (neo), providing resistant in the presence of the antibiotic 
geneticin (G418). G418, an aminoglycoside antibiotic produced by Micromonospora 
rhodorangea, can block peptide synthesis by inhibiting the elongation step in both 
prokaryotes and eukaryotes [29-31]. The neo gene expresses a phosphotransferase 
enzyme, able to hydrolyze G418, allowing cells to survive in media containing this 
antibiotic [32, 33]. 
The initial step in this experiment was to determine the optimal G418 
concentration to kill the majority of the cells over an extended period of time. NIH3T3 
cells grown in media containing G418 (50-800 µg/mL) were observed for cell viability 
over a four to five day period, known as a kill curve. The appropriate concentration of 
G418 was determined to be 400 µg/mL, killing NIH3T3 cells in four days.  
As state above, in order to develop stable cell lines using a selection marker, the 
plasmid of interest must contain a selection marker resistant gene. Unfortunately, the 
pMSCVGR130GFP plasmid lacked a neomycin resistance marker; therefore, a 
cotransfection was performed with the pmRFP plasmid, which contains the neo gene and 
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constitutively expresses the red fluorescent protein (RFP). The hypothesis is that the 
cotransfection with the pmRFP plasmid and the pMSCVGR130GFP plasmid will allow 
the cells to survive in media treated with G418, as well as stably express the molecular 
switch system.  
A 1:20 cotransfection (mRFP: GR130) with the transfection reagent Polyfect was 
performed in a cell culture dish. G418 (400 µg/mL) was added to the cells daily until 
colonies formed. Once colonies formed, they were placed in a 48-well plate with media 
containing G418 to screen for colonies that expressed the molecular switch system 
proteins. LG335 was added to the colonies, and then colonies were analyzed for green 
and red fluorescence. Green fluorescence indicated that the colonies possessed the 
functional molecular switch system, while red fluorescence showed that the colonies 
contained the plasmid with the antibiotic resistant gene.  
Figure 3.10 is a image of one of several colonies chosen that exhibited both green 
and red fluorescence, as well as daughter cells that are also fluorescent. Colonies 
possessing both green and red fluorescent were selected and then placed in 6-well plates 
with media containing 400 μg/mL of G418 to allow the generation of daughter cells to 
occur. Once daughter cells were generated, they were also examined for green and red 
fluorescence. As shown in Figure 3.11, a number of daughter cells emitted both green 
and red fluorescence (purple circle); however, this was not observed in all the daughter 
cells generated. Fluorescence was lost in the other daughter cells, black arrow. 
pMSCVIRESGFP was used as a positive control. This plasmid is not missing the 
selection marker gene; hence cells cotransfected with pMSCVIRESGFP and mRFP were 

















































































































































































































































































































































































































system with the selection marker plasmid allowed the production of cells that expressed 
the molecular switch system; however, expression of this system was lost over time, due 
to the fact that the colonies only needed the mRFP plasmid to survive. 
3.4.3 Genomic Analysis of NIH3T3 cells transduced with GR130 
Since stable expression of the molecular switch system could not be characterized 
through transient transfection and a selection marker, troubleshooting was performed 
with the retroviral transduced cells. Retroviral transductions provide the ability to 
integrate the molecular switch into the genome of the host. Integration of the transgene 
allows for the stable expression of a target gene for an extended period of time and over 
multiple generations of cells. To determine whether integration was successful, genomic 
DNA was purified from the transduced cells and primers were used to amplify regions of 
the molecular switch system. Sequencing results showed that the variant was not I268A, 
I310A, F313A, and L436F (GR130) but was Q275C, I310M, and F313I (GRQCIMFI). 
This plasmid was inherited prior to this thesis work from a previous lab member, and 
must have been mislabeled. 
In summary, a molecular switch system was characterized with what was thought to 
be the orthogonal ligand receptor pair (OLRP), GR130, which has a Gal4 DBD fused to a 
RXR variant (I268A, I310A, F313A, and L436F). In the presence of LG335, this 
transcription factor is shown to bind to Gal4 RE and activate both a luciferase and GFP 
genes. This system shows efficient gene expression in both two-component and one-
component systems. The one-component system was then transduced in NIH3T3 cells 
using retroviral particles after optimization with the control plasmid, pMSCVIRESGFP.  











































































































































QCIMFI (Q275C, I310M, F313I) rather than the GR130 variant. Therefore, the next 
chapter focuses on characterizing the molecular switch system using the QCIMFI variant. 
3.5 Materials and Methods 
Ligands 
9-cis-retinoic acid (MW 304.44 g/mol) and all-trans-retinoic acid (MW 300.44 
g/mol) were purchased from MP Biomedicals (Solon, OH). LG335 was synthesized in 
the lab [12, 34]. 10 mM stocks of the ligand were dissolved in 80% ethanol:20% DMSO 
and stored at 4ºC. 
Plasmids 
The p17*4TataRluc plasmid was previously constructed from p17*4TataFLuc (a 
gift from Dr Sofia Tsai, Baylor College, Houston, TX) [35, 36] by replacing the firefly 
luciferase with Renilla luciferase. The Renilla luciferase was cloned from pHRL 
(Clontech, USA) with NotI and SacII restriction sites. The internal standard plasmid 
pCMX-βGAL constitutively expresses β-galactosidase under control of the CMV 
promoter. The plasmids pCMXRXRwt, pCMXRXR130, pMSCVGR130, 
pMSCVGR130Talu, and pMSCVGRQCIMFITalu have been previously described [1, 
12]. The pLuc_CRPBII was made by site-directed mutagenesis from pLucMCS 
(Stratagene, USA). Site-directed primers were designed to incorporate a CRBPII 
response element in the multiple cloning site (MCS). 
Cell culture conditions 
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All cell types were maintained at 37°C in humidified air with 5% CO2. NIH3T3 
(ATCC, Manassas, VA) and HEK293T (ATCC, Manassas, VA) cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Mediatech Inc, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS, PAA Australia, ) and 1% 
penicillin/streptomycin (PS) (VWR, West Chester, PA), also known as growth media.  
Mammalian luciferase assays 
Transfections of HEK293T cells were performed in 48-well plates with 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as the cationic lipid as recommended by 
the manufacturer. Briefly, 20 ng of pMSCVGR130 or pCMXGRXRwt expression 
plasmid, 40 ng of p17*4TataLuc reporter plasmid, and 40 ng of pCMX-βGAL expression 
plasmid (used as an internal standard) were mixed with 0.3 μL of Lipofectamine 2000 in 
40 μL of Opti-Mem (Invitrogen, Carlsbad, CA) reduced serum media per transfected 
well. After incubating for 30-60 minutes, an additional 160 μL of Opti-Mem was added. 
The mixture with a total volume of 200 μL mixture was added to a well previously 
washed with 250 μL of Opti-Mem. Eight hours after the transfection, wells were 
aspirated and ligands diluted in growth media were added to the wells. Cells were 
harvested after 36-40 hours and assayed for luciferase and β-galactosidase activities. All 
data points represent the mean of triplicate experiments normalized against β-
galactosidase activity. Error bars represent the standard deviation. The one-component 
system, pMSCVGR130GFP was transfected as described above; however the 
p17*4TataLuc plasmid was not added to the transfection mixture. Data was analyzed in 
the graphing program Graph Pad Prism® using the nonlinear regression curving program 
called Dose-Response Stimulation: log(agonist) vs. response (three parameters). 
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Where xi is the RLU value, N is the number of samples measured, and x is the average 
RLU value. 
Mammalian GFP analysis 
Transfections of HEK293T cells were performed in 12-well plates with 
Lipofectamine 2000 cationic lipid as recommended by the manufacturer. Briefly, 1.6 μg 
of pMSCVGR130GFP or pMSCVIRESGFP was mixed with four μL of Lipofectamine 
2000 in 200 μL of Opti-Mem reduced serum media per transfected well. After 30-60 
minutes, an additional 1600 μL of Opti-Mem was added and the 2 mL mixture was added 
to a well previously washed with 2 mL of Opti-Mem. After eight hours of transfection the 
wells were aspirated and ligands diluted in growth media were added to the wells. Images 
of transfected cells were taken using a 40X objective on a Zeiss LSM microscope. 
Images were processed on Adobe Photoshop. To obtain the percentage of fluorescent 
cells, the number of fluorescent cells counted was divided by the total number of cells 
counted multiplied 100. 
Transfection into Packaging Cell Line 
EcoPack-293T cells (Clontech, USA) were transiently transfected with 16 μg of 
pMSCVGRQCIMFIGFP or pMSCVIRESGFP plasmid with 20 μL of Lipofectamine 
2000 and 6 mL of Opti-Mem in a 100 mm cell culture dish. After eight hours, the media 
was changed to 7 mL of growth media. Collected viral particles in media on cells every 
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10-15 hours and filtered with a 0.45 μm syringe filter (Pall Corporation, USA) for five 
consecutive days.  
Concentration of Virus 
 Viral stock were thawed in a waterbath at 37
o
C, and centrifuged at 13800 x g 
overnight (minimum 16 hours) at 4
o





 of the original volume of media. 
Retroviral Transduction 
   Media contain retroviral infectious particles was incubated with 80 μg/mL of 
chondroitin 6-sulfate sodium salt from shark cartilage (CSC, Sigma Aldrich, USA) for 10 
minutes, and then with 80 μg/mL of polybrene (PB, Millipore Corporation, USA) for 10 
minutes. Media was then added to NIH3T3 cells grown on 6-well plates with 8 μg/mL of 
polybrene. 
Flow Cytometry Data 
 NIH3T3 cells transduced with the IRESGFP retroviral infectious particles were 
tryspinized and resuspended in growth media. Fluorescent intensity was then measured 
and analyzed using the BD LSR instrument. 
Transfection using selection marker 
NIH3T3 cells were cotransfected with 1 µg of pmRFP and 20 µg 
pMSCVGR130GFP with 44 µL of the transfection reagent PolyFect (Qiagen, USA). 
Geneticin (HyClone Laboratories, Utah) was diluted in growth media to a concentration 
of 400 µg/mL and 10 mL of media containing the antibiotic was added to the cells daily 
until colonies formed. Colonies were picked with a pipette tip and placed in a 48-well 
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plate with 250 µL of growth media containing 400 µg/mL of geneticin. Colonies were 
analyzed for green and red fluorescence using the 40X objective on a Zeiss LSM 
microscope. Cells displaying both green and red fluorescence were placed in 6-well 
plates with 2 mL of growth media containing 400 µg/mL of geneticin for further growth. 
Once cells reached confluency in the 6-well plate were then trypsinzed and then placed in 
35 mm dish with 4 mL of growth media containing 400 µg/mL of geneticin. Cells were 
then analyzed again for green and red fluorescence using a 40X objective on a Zeiss LSM 
microscope. Images were processed on Adobe Photoshop. 
Genomic Analysis 
 NIH3T3 cells transduced with retrovirus were harvested and purified using the 
DNeasy kit (Qiagen, USA). Sections of the molecular switch system were amplified from 
the genomic DNA and submitted for sequencing (Eurofins/MWG/Operon, Alabama). 
Sequencing primers used to confirm variant were: 1f’, ATT CTT TAC AGG ATA TAA 
AAG CAT TGT TAA CAG GAT; 1r’, CGC CTC CAG CAT CTC CAT AAG G. 
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CHARACTERIZATION OF THE QCIMFI VARIANT IN THE 
MOLECULAR SWITCH SYSTEM 
 
4.1 Engineering the QCIMFI Variant 
As mentioned in Chapter 3, the retinoid X receptor (RXR) variant that was thought 
to be GR130 (adopted from the previous Doyle lab member Priyanka Rohatgi) was 
actually the Q275C, I310M, and F313I (QCIMFI) variant. Previously, the QCIMFI 
variant was engineered through rational design and site directed mutagenesis to have 
reverse ligand specificity, binding and activating in response to LG335 and not RXR’s 
natural ligand 9cRA [1]. 
The luciferase activation profile of this variant was determined using a reporter 
plasmid containing RXR response elements controlling expression of the firefly luciferase 
gene (pLuc_CRBPII) [2]. As shown in Figure 4.1, the QCIMFI variant, in the 
mammalian expression vector pCMXRXRQCIMFI, and the pLuc_CRBPII plasmids 
were cotransfected into HEK293T cells at a 1:2 molar ratio, and then cells were treated 
with a range of LG335 and 9cRA concentrations. The activation profiles show the 
QCIMFI variant is activated in response to LG335 (pink line) at concentrations as low as 
100 nM (EC50 value is 38 nM) with a 14.5 ± 1.6-fold induction. No activation was 
observed with 9cRA (purple line shown in Figure 4.1). Conversely, the wild type (wt) 
RXR is activated by 1 μM 9cRA (EC50 value is 597 nM) with a 13.4 ± 4.2-fold induction 
(blue line) and is activated by LG335 at the same concentration (EC50 value is 338 nM) 
















Figure 4.1: Activation Profiles of RXRwt and QCIMFI: Dose response curves for the 
activation of full length wild-type RXR (RXRwt) and RXR variant Q275C I310M F313I 









variant is orthogonal to the synthetic ligand LG335 and is not activated by the 
endogenous ligand 9cRA.  
Figure 4.2 displays the fold induction at different concentrations of LG335 with 
QCIMFI and RXRwt. QCIMFI is activated at lower concentrations of LG335 and has 
much higher fold inductions, displaying a 10-fold induction at 100 nM LG335, when 
compared to RXRwt, which shows a 4-fold induction at 0.3 µM LG335. The reverse 
ligand specificity, high fold induction, and relatively low EC50 value were comparable to 
results observed by Doyle et al and led to the development of a molecular switch system 
using the QCIMFI variant and the ligand LG335. This chapter will address the 
characterization of the QCIMFI variant as a potential molecule switch. Characterization 
of this system involves first assessing the system through transient transfection in a two-
component and a one-component system, as well as through stable expression of the one 
component system using retroviral particles.  
4.2 Characterization of GRQCIMFI in the Two-Component System 
As mentioned in Chapter 3, the DNA binding domain (DBD) of nuclear receptors 
(NR) must be switched to a Gal4 DBD in order to prevent binding of the molecular 
switch to endogenous NR response elements (RE). Gal4 is a yeast transcription factor 
that initiates transcription of genes controlled by Gal4 RE [3-5]. Removal of the NR’s 
natural DBD provides specificity towards the molecular switch, allowing the expression 
of a therapeutic gene in response to the synthetic ligand and an artificial promoter.  
To assess the activation of the QCIMFI variant in the two-component molecular 
switch system, the variant was previously cloned into the pMSCV plasmid and fused to 


















Figure 4.2: Fold Inductions of RXRwt and QCIMFI: Fold inductions of RXRwt (black 




plasmids. The first plasmid, pMSCVGRQCIMFI, constitutively expresses the 
GRQCIMFI variant (Gal4 DBD fused to the RXR variant QCIMFI LBD). The second 
plasmid, p17*4TataLuc, contains four Gal4 RE located upstream from the thymidine 
kinase promoter controlling expression of Renilla luciferase. These two plasmids were 
cotransfected into HEK293T cells at a 1:2 molar ratio respectively, and tested with a 
range of both LG335 and 9cRA concentrations.  
As shown in Figure 4.3A, the two-component system induces expression of 
luciferase at 100 nM LG335 (EC50 value of 11 nM) leading to a 6 ± 2-fold induction ratio 
of luciferase activity, shown in pink. Activation with 9cRA, shown in blue, only occurs at 
the highest concentration of ligand, 10 μM 9cRA (EC50 value is greater than 10 μM) with 
a 5±1-fold induction. As a positive control, the Gal4 DBD was fused to the RXRwt LBD 
(GRXRwt) and assessed for luciferase activity (Figure 4.3B). GRXRwt displayed an 
EC50 value of 100 nM and a 4±1-fold induction in the presence of 9cRA, shown in blue; a 
320 nM EC50 value and a 5±2-fold induction were observed with LG335, shown in pink. 
The GRQCIMFI variant has a lower EC50 values in response to LG335 when compared 
to the control GRXRwt, as well as comparable fold induction. As stated in Chapter 3, the 
activation of GRXRwt by LG335 is not of any concern since the fusion protein does not 
exist in vivo. As expected, these results show that the GRQCIMFI variant is specific to 
the synthetic ligand LG335 in the molecular switch system. 
4.3 Interference with Metabolic Pathways 
To determine if GRQCIMFI was only able to bind the Gal4 RE and turn on 
transcription with LG335, a series of luciferase activity assays were performed with 


















Figure 4.3: Activation Profiles of GRQCIMFI and GRXRwt: Luciferase assay of 
GRQCIMFI (Gal4 DBD-RXR variant QCIMFI LBD) and GRXRwt (Gal4 DBD-RXRwt) 




induce expression of the target gene controlled by Gal4 RE. A combination of plasmids 
containing GRQCIMFI or RXRwt (pMSCVGRQCIMFI or pCMXRXRwt) along with 
reporter plasmid (p17*4TataLuc or pLuc_CRBPII) were cotransfected into HEK293T 
cells at a 1:2 molar ratio, respectively, with no ligand and with 1 μM ligand (LG335, 
9cRA, and all-trans retinoic acid (atRA)). The plasmid pCMXRXRwt contains full 
length RXRwt under the control of a cytomegalovirus (CMV) promoter, and as stated 
previously, the pLuc_CRBPII plasmid contains RXR response elements controlling 
expression of firefly luciferase. The concentration 1 µM of ligand was chosen, since 
previous results showed that 9cRA activates the molecular switch at a concentration of 10 
µM. Therefore, this experiment examines the activation of GRQCIMFI and RXRwt with 
ligands at a lower concentration. 
 Figure 4.4 shows the cotransfection of pMSCVGRQCIMFI and p17*4TataLuc 
resulted in a 4.5 ± 1.1-fold induction in the presence of 1 μM LG335. Only a 1.2 ± 0.3-
fold induction is observed with 9cRA, and a 2.1 ± 0.5-fold induction with atRA. 
Activation does not occur when pMSCVGRQCIMFI is cotransfected with pLuc_CRBPII, 
as expected, due to the fact that the Gal4 DBD should not and does not bind to the RXR 
RE. Conversely, when pCMXRXRwt and pLuc_CRBPII plasmids are cotransfected, the 
highest activation occurs in the presence of both 9cRA and atRA, with fold inductions of 
10.1 ± 3.0 and 5.7 ± 1.0, respectively. RXRwt is slightly activated in response to LG335 
with a 4.5±1.1-fold induction; however, this result was not surprising since previous 
results showed activation of RXR at 1 µM LG335 (Figure 4.1). When pCMXRXRwt is 
cotransfected with p17*4TataLuc, minimal activation occurs since the RXR DBD does 
















Figure 4.4: Luciferase Assays in the Presence of 1 µM Ligand: Luciferase assays in the 
presence of 1 μM different ligands: LG335, 9cRA, or atRA. Constitutively expressed 
GRQCIMFI or RXRwt were cotransfected with p17*4TataLuc or pLuc_CRBPII. These 





endogenous RE and ligands shows that the engineered transcription factor has specificity 
to its target enhancer region and is orthogonal to the ligand LG335. [7, 8]. One drawback 
to this system is the slight activation observed with RXRwt in response to LG335; 
however, the fold induction is approximately half the fold induction of RXR with 9cRA. 
The results above show a two-component molecular switch system was developed 
using the ligand LG335 and the fusion of the Gal4 DBD and the RXR variant QCIMFI 
LBD. Activation of a transgene with LG335 occurred at levels as low as 100 nM, and 
was only observed with the wild-type ligand at a concentration of 10 µM. GRQCIMFI 
displays orthogonal behavior with LG335, activating expression of a target gene 6-fold, 
and binding specific DNA sequences called Gal4 RE, exhibiting tight control over the 
target gene. Activation occurs only when pMSCVGRQCIMFI and p17*4TataLuc, the 
plasmid containing Gal4 RE, were cotransfected and 100 nM LG335 was added to the 
cells. No activation above basal activity occurred when pMSCVGRQCIMFI was 
transfected under different conditions. The engineered switch with the Gal4 DBD 
responds appropriately to the Gal4 RE and not with endogenous RE. 
4.4 Ligand Time Course 
As previously described in Chapter 2, the activation of a molecular switch system 
should correlate with the ligand dosage. The addition of ligand should rapidly induce 
target gene expression, and the removal of ligand should show a rapid decrease of target 
gene expression. Many molecular switch systems have evaluated how ligand dosage 
correlates to gene expression in various systems. For instance, the GeneSwitch regulation 
system has shown protein expression 24 hours after administration of mifepristone 
(RU485) in a mouse model, and expression of this protein returned to basal expression 
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levels 72 hours after the ligand is removed [9]. The doxycycline ligand, a tetracycline 
analog used in the tetracycline inducible system, is a well documented ligand and has 
been used for over 30 years [10]. This ligand has been shown to induce gene expression 
in animal models five years after administration of the viral vector [11-13].  
To understand the rate at which LG335 induces expression of the target gene, as well 
as the rate that the target gene expression decreases, a ligand time course assay was 
performed.  As shown in Figure 4.5, several subsets of data were collected and averaged, 
where HEK293T cells were cotransfected with pMSCVGRQCIMFI and p17*4TataLuc at 
a 1:2 molar ratio. In the first data set, shown in red, the basal activity of this system was 
tested by transfecting cells with plasmids and assaying for luciferase activity. No ligand 
was added in this data set. The second and third data set, shown in blue and green 
respectively, were also transfected with the pMSCVGRQCIMFI and p17*4TataLuc 
plasmids, but 100 nM LG335 was added eight hours after the transfection. Both data sets 
were also assayed for luciferase activity; however, data set three was washed with growth 
media 32 hours after the transfection to remove LG335, a time point chosen after full 
activation is reached.  
As shown in Figure 4.6, LG335 induces luciferase activity 24 hrs after ligand is 
added, and activation increases up to 56 hours after the transfection. This is observed if 
the ligand is not removed from the media, as shown in data set two (blue bars). A slight 
decrease in luciferase activity is observed after 56 hours, which could be due in part to 
the viability of the cells. In the third data set (green bars), when ligand is removed 32 
hours after transfection, an immediate decrease in luciferase activity is observed at the 40 
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hour time point. The decrease of activation is observed until the 88 hour time point; 
however, basal activity is not observed.  
These results show LG335 can induce transgene activation within 24 hours of adding 
ligand, and the ligand activation increases for about 56 hours after induction. The 
prolonged activation by the ligand, as well as the slow decrease to basal levels is not 
surprising, due to the fact that LG335 is a very stable compound. LG335 has a high 
melting temperature of 250-252
o
C and the parent compound, Targretin, is known to have 
a seven hour half-life when introduced into the body [14]. To further understand how this 
ligand behaves in this molecular switch system, the ligand time course needs to be 
assessed when stable expression of this system is achieved. Stable expression allows a 
more accurate assessment of the rate of gene activation and decrease since transient 
transfection factors are eliminated, such as the retention of the plasmid. Also to further 
understand the pharmacology of this ligand, in vivo analysis of LG335 would be 
extremely useful for toxicity studies, as well as determining the rate of metabolism of 
LG335.  
4.5 Characterization of GRQCIMFI in the One-Component System 
As established in Chapter 3, the one-component system has higher transfection 
efficiency than the two-component system.  Therefore, GRQCIMFI was cloned into the 
one-component system plasmid by removing GR130 from the retroviral vector 
(pMSCVGR130GFP), replacing the gene with GRQCIMFI (pMSCVGRQCIMFIGFP). 
As stated previously, this plasmid constitutively expresses GRQCIMFI, and upon the 
addition of LG335, the molecular switch can bind to the Gal4 RE on the same plasmid 














Figure 4.5: Ligand Time Course Flow Chart: Experimental design of three sets of data 
collected to determine basal expression levels (set 1), when gene expressed is induced 





































Figure 4.6: Ligand Time Course Data: HEK293T cells were transfected with 
pMSCVGRQCIMFI and p17*4TataLuc and 8 hours after transfection 100 nM of LG335 
was added to cells. Ligand was removed 32 hours after transfection. Cells were harvested 
every 8 hours for the ligand time course. The addition of LG335 is shown in (■), the 






















transfected into HEK293T cells and treated with no ligand, 10 nM and 10 μM LG335 to 
evaluate this variant in the one-component system (Figure 4.7). Images of transfected 
cells were taken 48 hours after the transfection, and the percentage of fluorescent cells 
was obtained.  
The results in Figure 4.7 show that without ligand, basal GFP expression is 
observed where approximately 7% of the cells are dimly fluorescent. Upon the addition 
of 10 nM LG335 the intensity of the fluorescence increases and approximately 10% 
exhibit GFP expression. In the presence of 10 M LG335 the expression of GFP is 
detected in about 30% of HEK293T cells, verifying the increase in percent fluorescent 
cells as the ligand concentration increases (Figure 4.7). The GFP expression in the one-
component system was compared to a control plasmid pMSCVIRESGFP, which 
constitutively expresses eGFP. This plasmid contains a internal ribosome entry site 
(IRES) that allows the translation of RNA to occur more effectively, and was used to 
evaluate transfection efficiency. As shown in Figure 4.8, the IRESGFP plasmid shows 
GFP expression in approximately 60% of the cells. As expected, the one-component 
system with the GRQCIMFI variant shows tight regulation of GFP expression. Therefore, 
both two-component and one-component systems showed that the molecular switch 























Figure 4.7: Transient Transfection of GRQCIMFIGFP: DIC, fluorescent, and overlay 
images of HEK293T cells transfected with GRQCIMFIGFP in the presence of no ligand, 


























Figure 4.8: Transient transfection of pMSCVIRESGFP: The DIC and fluorescent 




4.6 Characterization of Stable Expression of GRQCIMFI in the 
Molecular Switch System 
As mentioned in Chapter 3, stable expression of the molecular switch system was 
assessed by transducing cells with retroviral particles. Retroviral particles can be made by 
transiently transfecting the pMSCVGRQCIMFIGFP vector into the EcoPack 2-293 
packaging cell line and infectious retroviral particles were collected and transduced into 
NIH3T3 cells. These cells were then analyzed for integration of the virus into the cellular 
genome. 
To determine integration of the molecular switch sequence, a genomic extraction of 
NIH3T3 cells was collected using the Qiagen DNeasey Blood & Tissue kit and analyzed 
by nesting PCR. Nesting PCR is a technique where two sets of primers are used to 
amplify DNA in two consecutive polymerase chain reactions (PCR). The second set of 
primers is needed to eliminate amplification of non-specific DNA strands. As shown in 
Figure 4.9, PCR experiments were performed with primers that annealed to separate 
regions of the four kilobase one-component system. Primer set 1 (1f and 1r) annealed to 
the GRQCIMFI region; whereas primer set 2 (2f and 2r) amplify the region containing 
Gal4 RE and eGFP.  Both primer sets 1 and 2 were used in PCRs with genomic DNA, 
and secondary PCRs were done with primer sets 1’ (1f’ and 1r’) and 2’ (2f’ and 2r’) to 
confirm the sequence of interest was being amplified. As a positive control, these 
experiments were performed with plasmid DNA, and the sizes of the amplified cassettes 
were compared with the sizes of the genomic DNA. Figure 4.9 shows the PCR fragments 
from the genomic DNA are the same size as predicted, suggesting that cellular integration 
occurs without transgene rearrangement. Genomic PCR fragments were also confirmed 
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by sequencing. These results indicated that administrating this system through a 
retrovirus successfully integrated the molecular switch sequence into target cells. 
To assess the regulation of the stable molecular switch system, NIH3T3 cells 
transduced with GRQCIMFIGFP were grown in media with no LG335 or 10 M LG335 
for 24 hours. These results show that without the presence of ligand, GFP fluorescence is 
not observed (Figure 4.10), whereas 34% of the cells were fluorescent upon the addition 
of 10 M LG335, further confirming this system as a useful tool for controlling gene 
expression. The positive control pMSCVIRESGFP shows GFP expression in 70% of 
cells with a higher fluorescent intensity in comparison to the molecular switch system 
(Figure 4.11). The low fluorescence intensity led to the evaluation of the transduction 
efficiency of the molecular switch system. 
In summary, the molecular switch was developed to address the criteria stated in 
Chapter 2, which include the turning on and off of transgene expression upon the addition 
of LG335. Even though the molecular switch system can proficiently regulate gene 
expression, improvements are needed to make this system more versatile for gene therapy 
applications. The ligand, LG335, is specific to the engineered protein GRQCIMFI; 
however, this exogenous ligand can slightly activate RXRwt, which may cause 
interference in metabolic pathways. Therefore, this switch could be further engineered to 
be activated at a lower dosage in order to reduce activation by the wild type receptor. The 
molecular switch system is able to induce expression of the target gene in transient 
transfections, as well as retroviral transduction; however, the stable expression of GFP is 
only observed at a low fluorescent intensity. The next chapter will attempt to address 














Figure 4.9: PCR of Genomic DNA of Cells Transduced with GRQCIMFIGFP: PCR 
of genomic DNA purified from NIH3T3 cells transduced with virus. (A) is a schematic 
diagram of where the primers bind in the molecular switch system, and (B) the 





















Figure 4.10: Fluorescent Images of Cells Transduced with GRQCIMFIGFP: 
Fluorescent images of NIH3T3 cells transduced with GRQCIMFIGFP in response to no 























Figure 4.11: Fluorescent Images of Cells Transduced with IRESGFP: The DIC and 




4.7 Materials and Methods 
Mammalian Luciferase Assay 
 Transfections of the two-component systems with the GRQCIMFI variant were 
performed as described in Chapter 3. 
Ligand time course 
The transfection for this assay was performed as described in Chapter 3. 
HEK293T cells were transfected with the pMSCVGRQCIMFI and p17*4TataLuc 
plasmids at a 1:2 ratio. Eight hours after the transfection, the batch of cells from data set 
1 were placed in growth media lacking ligand, and the batch of cells from data set 2 and 3 
were placed in growth media with 100 nM LG335. As described in Chapter 3, growth 
media is DMEM with 10% FBS and 1% P/S. Cells were harvested every 8 hours for 
luciferase and -galactosidase activity, also described in Chapter 3. Media with 100 nM 
LG335 was removed from the batch of cells from data set 3, 32 hours after transfection 
and placed in growth media with no ligand. Cells were continuously harvested for 88 
hours after transfection. Two experimental data sets were taken and each set was divided 
by the maximum RLUs and multiplied by 100 to receive the percent maximal RLUs. 
Then the average and standard deviation of both sets were calculated. 
Mammalian GFP Analysis 
 HEK293T cells were transfected with the pMSCVGRQCIMFIGFP plasmid as 
described in Chapter 3. Eight hours after the transfection, wells were aspirated and then 
growth media containing no ligand, 100 nM LG335, and 10 µM LG335 were added to 
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the wells. Fluorescent images and data processing was evaluated as described in Chapter 
3. 
Retroviral Transduction 
Retroviral infectious particles were made with the pMSCVGRQCIMFIGFP 
vector as described in Chapter 3. NIH3T3 cells were transduced with 100 µL of viral 
incubated with CSC and PB, and then 10 µM LG335 was added to a subset of transduced 
cells. To obtain the percentage of fluorescent cells, the number of fluorescent cells 
counted was divided by the total number of cells counted multiplied by 100. Images of 
transduced cells were taken using a 40X objective on a Zeiss LSM microscope, and 
processed using Adobe Photoshop. 
Genomic PCR 
Genomic DNA was extracted from NIH3T3 cells transduced with GRQCIMFIGP 
retrovirus using the DNeasy kits (Qiagen, USA). To clone the 1029 bp DNA sequence 
GR130 from genomic DNA, a primary PCR was performed using the following primers: 
1f, CCT TGA CAT GAT TTT GAA AAT GG; 1r, GCC GCC TAA GTC ATT TGG TG. 
Then a secondary PCR was performed with the following primers: 1f’, ATT CTT TAC 
AGG ATA TAA AAG CAT TGT TAA CAG GAT; 1r’, CGC CTC CAG CAT CTC 
CAT AAG G. To clone out the 1650 bp DNA sequence, containing the Gal4 RE and 
eGFP, a primary PCR was done with the following primers: 2f, GAG GTG GAG TCG 
ACC AGC AG; 2r, TTA CTT GTA CAG CTC GTC CAT GC. A secondary PCR was 
done with the following primers: 2f’, CGC CAA CGA GGA CAT GCC G; 2r’, CGA 
GAG TGA TCC CGG CGG C. The same sets of primers were used on the 
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pMSCVGR130GFP plasmid for size comparisons. Pfu polymerase (Stratagene, USA) 
was used, and the PCR fragments were analyzed on a 1.2% agarose gel. 
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5.1 Improving the Fold Induction Using VP16 
The molecular switch system described in Chapter 4 is shown to be able to 
regulate gene expression. However, the fluorescence intensity of GFP (green fluorescent 
protein) was significantly lower in cells infected with the GRQCIMFIGFP retrovirus in 
comparison to cells transiently transfected with the one-component system. Therefore, 
the next goal was to increase the fold induction of the molecular switch system and 
increase the sensitivity towards the ligand LG335. This chapter will discuss adding an 
activation domain to the molecular switch system, as well as performing mutagenesis in 
an attempt to discover a new variant with a higher fold induction and/or increased 
sensitivity towards LG335. 
5.1.1 Addition of the Activation Domain  
The VP16 protein consists of 490-amino acids, the key protein in the herpes 
simplex virus, and contains a core region and a C-terminal transcriptional activation 
domain [1, 2]. The activation domain of VP16 is considered to be a very potent 
transactivator, since the amino acid sequence is known to have strong interactions with 
several general transcription factors, such as the TATA-binding protein (TBP), TFIIB, 
and the Spt-Ada-Gcn5 (SAGA) histone acetyltransferase complex [1]. Hence, 
transcription occurs more efficiently in the presence of this domain.  
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Several molecular switch systems have used an activation domain as a means to 
improving the fold induction of their molecular switch system. In the initial development 
of the GeneSwitch® system, the Gal4 DBD was fused to a mutant progesterone receptor 
(PR) ligand binding domain (LBD), and when tested in mammalian cell culture, no 
significant activation was observed with the RU486 ligand. Therefore, the VP16 
activation domain was fused to the C-terminus region of this chimeric protein, enhancing 
the activation approximately 50-fold [3]. The VP16 activation domain was then replaced 
with the human p65 activation domain, a transcription factor that is a member of the 
NFκB family, to minimize basal activation levels and reduce possible immunogenic 
reactions [4-6]. The Ecodysone (EcR) responsive system (also known as Rheoswitch®) 
has also gone through several rounds of improvement. The VP16 activation domain was 
fused to the chimeric protein composed of the Gal4 DBD fused to the ecodysone 
receptor, as well as to the LBD of RXR [7-9]. The most current Rheoswitch® system, 
which consists of two fusion proteins, a hybrid DBD between EcR and the glucocorticoid 
receptor fused to an EcR LBD, and a RXR LBD fused to the VP16 activation domain, 
has approximately a 10,000-fold induction [9]. 
In an effort to increase the fold induction of the molecular switch described in 
Chapter 4, the VP16 activation domain was fused to GRQCIMFI. The fusion protein was 
created by amplifying VP16 from pVP16, a mammalian plasmid, and cloning the gene 
into the pMSCVGRQCIMFI plasmid, which contains the molecular switch GRQCIMFI 
(Figure 5.1). GRQCIMFI consists of the Gal4 DNA binding domain (DBD) fused to a 
RXR variant LBD with the following mutations: Q275C, I310M, and F313I. The first 











Figure 5.1 Cloning VP16 into pMSCVGRQCIMFI: MfeI and AvrII restriction enzyme 
sites were inserted into the pMSCVGRQCIMFI plasmid. VP16 was amplied from the 
pVP16 plasmid with primers containing MfeI and AvrII restriction sites. The vector 
cassette and insert cassette wither digested and ligated together to create the pMSCV 
VP16-GRQCIMFI plasmid.  
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 AvrII into the pMSCVGRQCIMFI vector at the N-terminus region of GRQCIMFI via 
site-directed mutagenesis. Then the VP16 domain was cloned out the pVP16 plasmid 
(provided by the Ortlund lab, Emory University) using primers containing MfeI and AvrII 
restriction enzyme sites. The VP16 insert cassette and the pMSCVGRQCIMFI vector 
cassette were then digested with the MfeI and AvrII restriction enzymes, and ligated 
together to create the new plasmid, pMSCV VP16-GRQCIMFI, confirmed by sequencing 
(Figure 5.1).  
The pMSCV VP16-GRQCIMFI plasmid, which constitutively expresses VP16-
GRQCIMFI, was cotransfected with the p17*4TataLuc plasmid into HEK293T cells. The 
plasmid, p17*4TataLuc, contains Gal4 response elements (RE) controlling expression of 
Renilla luciferase. As shown in Figure 5.2A, the addition of VP16 to GRQCIMFI 
displayed a 1.8±0.2-fold induction in response to 9cRA and a 0.8±0.2-fold induction with 
LG335. Since high relative light units (RLU) were observed, the addition of the VP16 
activation domain created a constitutively active protein. This activation profile was 
compared to the GRQCIMFI profile, which lacked the activation domain, and showed a 
5±1-fold induction with 9cRA and a 6±1-fold induction with LG335. This data confirms 
results observed previously by  Lipkin et al, who also observed a constitutively active 
receptor upon the addition of the VP16 AD to the C-terminus domain of wild type RXR 
[10]. The addition of VP16 did not increase the fold activation of this system; hence, 
another route was pursed in order to improve the molecular switch system.  
5.2 Discovery and Characterization of the Quadruple Mutant QCIMFILM 
The next approach used to improve the molecular switch was exploring mutations 










Figure 5.2 Activation profiles of VP16-GRQCIMFI and GRQCIMFI: Activation 
profile of HEK29T cells transfected with VP16-GRQCIMFI and GRQCIMFI in response to 
LG335 (●) or 9cRA (■) Table of fold inductions for each ligand.
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engineered RXR libraries using rational design produced two RXR variants discussed in 
previous chapters, GR130 (I268A, I310A, F313A, and L436F) and QCIMFI (Q275C, 
I310M, and F313I) that displayed reverse specificity, activated by the synthetic ligand 
LG335 and not the natural ligand 9-cis retinoic acid (9cRA) [11, 12]. However, further 
rational design approaches did not produce RXR variants with increased sensitivity 
towards LG335 without also increasing sensitivity towards the natural ligand. Therefore, 
random mutagenesis was used to develop libraries of RXR variants that were subjected to 
chemical complementation, in an attempt to discover a new variant that is able to activate 
the receptor at lower concentrations of LG335 than the QCIMFI variant. 
5.2.1 Chemical Complementation 
Chemical complementation (CC) is a genetic selection system that links the 
binding and activation of a nuclear receptor by a small molecule to the survival of 
Saccharomyces cerevisia. CC was established in the PJ69-4A strain, based on a third 
generation yeast-two hybrid system [13]. This strain contains Gal4 response elements 
(RE) controlling expression of genetic selection genes, such as ADE2 or HIS3. Gal4 is a 
ligand independent yeast transcription factor, containing a DNA binding domain (DBD) 
that binds the Gal4 RE and a activation domain, involved in recruiting the transcription 
machinery [14].  
To develop CC, the genetic selection genes, specifically ADE2, which encodes for 
a key enzyme involved in the adenine biosynthetic pathway, was utilized. Expression of 
the ADE2 gene allows the yeast to survive in media lacking adenine.  To link a small 
molecule to the expression of the ADE2 gene, a three-component system was created, 
consisting of a Gal4 DBD fused to the RXR LBD (GBD-RXR), the coactivator ACTR 
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(activator for thyroid hormone and retinoid receptor) fused to the Gal4 activation domain 
(ACTR-GAD), and a small molecule [11, 15]. When a ligand binds to GBD-RXR, a 
conformation change takes place, allowing the recruitment of ACTR-GAD, leading to the 
expression of the ADE2 gene (Figure 5.3). Therefore, in the presence of a small molecule 
the yeast are able to survive in media lacking adenine (ligand-activated growth). 
In order to use CC experimentally, yeast expression plasmids must be transformed 
into the PJ69-4A strain. As shown in Figure 5.4, the GBD-RXR fusion protein contains a 
tryptophan (W) marker (pGBDRXR), and the plasmid containing the ACTR-GAD fusion 
protein contains a leucine (L) marker (pGAD10BAACTR). Both plasmids were 
transformed in the yeast strain and plated on synthetic complete media (SC) lacking 
leucine and tryptophan (SC-LW). This media is called nonselective media, since the 
presence of a ligand is not needed for the yeast to survive.  
5.2.2 Creation of RXR Libraries Using Random Mutagenesis 
Chemical complementation is a relatively easy and fast method used to evaluate 
ligand-activated growth of NR, and is comparable to mammalian cell assays. This 
selection system can also be used as a tool to evaluate variant receptors that are 
engineered to bind novel small molecules. RXR has been characterized in chemical 
complementation with several ligands, and several RXR libraries have been transformed 
in this yeast strain to select for variants activated by novel small molecules [11, 16, 17]. 
Hence, this system was used to select for RXR variants that were activated at a lower 
concentration of LG335. 
 Previously, rational design has been used to engineer nuclear receptor variant to 









Figure 5.3: Chemical Complementation System: This system is established in the PJ69-
4A strain, which contains Gal4 RE controlling expression of the genetic selection gene, 
ADE2. When the ligand LG335 binds to the RXR LBD-Gal4 DBD fusion protein, the 









Figure 5.4:  Transformation of pGAD10BAACTR and pGBDRXR into the PJ69-4A 
strain: The yeast plasmids pGAD10BAACTR and pGBDRXR were transformed into the 
yeast strain PJ69-4A and then placed on nonselective plates containing synthetic 




exploring mutation space. Error prone polymerease chain reaction (epPCR) is a simplistic 
and versatile method that allows a larger mutational range to be explored [18]. In this 
method, DNA strands are amplified using a commercial polymerase. The fidelity or the 
error rate of the polymerase can be increased by manipulating the parameters of the PCR 
conditions [18]. The Taq polymerase is a thermostable enzyme from Thermus aquaticus 
that catalyzes the synthesis of DNA, but lacks proofreading capability, hence, a high error 
rate [18, 19].  To further increase the error rate of Taq polymerase, MnCl2 was added to 
the PCR reaction. Manganese II is a metal that has the same oxidation number as 
magnesium, the cofactor of the Taq polymerase, but increases the mismatching frequency 
of this enzyme [18, 20]. Various concentrations of MnCl2 (2 M, 20 M, and 200 M) 
were used to amplify three different RXR templates, GR130, GRQCIMFI, and RXRwt, 
making a variety of insert cassettes. The insert cassettes have ends that are 
complementary to the background plasmid (pGBDRXRBP). 
The previously cloned background plasmid, pGBDRXRBP, contains the Gal4 
DBD fused to the RXR LBD; however, a random DNA sequence is inserted into the 
RXR LBD, creating multiple stops in the sequence [17]. The purpose of introducing stop 
codons into the background plasmid is to eliminate RXR wild type background. When 
both cassettes are transformed into the PJ69-4A strain, as shown in Figure 5.5, the insert 
cassette combines with the background vector via homologous recombination, allowing 
the expression of multiply full length fusion protein, GBD-RXR, with an assortment of 
mutations. The transformants were then placed on nonselective plates, synthetic complete 
(SC) lacking leucine and tryptophan (SC-LW) to access the transformation efficiency and 









Figure 5.5: Creation of RXR Library and transformation into PJ69-4A strain: The 
background plasmid contains regions of homology with the insert cassette. The insert 
cassette contains a variety of mutations (x) at random positions. The insert cassette can 
combine with the background plasmid when transformed into yeast, creating various 




were also placed on adenine selective media, SC media lacking adenine, leucine and 
tryptophan (SC-ALW), containing a desired small molecules. If the small molecule can 
bind and activate the receptor, then ACTR-GAD will be recruited and turn on expression 
of the ADE2 gene, allowing the survival of yeast in adenine selective media. Since the 
GRQCIMFI variant displays growth at a concentration of 1 M LG335 in CC, the 
adenine selective plates contained 100 nM LG335. 
5.2.3 Results of RXR Error Prone Libraries 









 variants respectively, determined from the 
nonselective plate and are summarized in Table 5.1. However, RXRwt libraries had very 
low transformation efficiencies (275-950 cfu/µg DNA) and library sizes (14-48 variants), 
and produced no potential ligand-activated variants. The RXRwt libraries were repeated; 
however, no variants were produced with higher sensitivity towards LG335 than the 
QCIMFI variant. 
The GR130 and GRQCIMFI libraries resulted in several potential ligand-
activated variants, since colonies formed on adenine selective plates with 100 nM LG335. 
Therefore, these variants were tested on solid media for constitutive activity. 
Constitutively active variants display growth regardless of the present of ligand. As 
shown in Figure 5.6, 100 colonies (~0.1-2% of each library) were streaked onto 
nonselective (SC-LW) and adenine selective (SC-ALW) plates. The streaking results 
showed that most of the colonies streaked were not constitutive active, displaying no 

















Figure 5.6: Streaking Results of RXR Variants for Constitutive Activity: 
Streaking results of RXR variants on adenine selective (SC-ALW) and 





The variants were further tested on solid media for activation at lower 
concentrations of LG335. Sixty potential colonies were streaked onto adenine selective 
plates with and without LG335. As shown in Figure 5.7, only three variants, circled in 
red, displayed ligand-activated growth, showing growth only on adenine selective plates 
with LG335. One variant was constitutively active, yellow arrow, growing regardless of 
the presence of ligand. As expected, Gal4, blue arrow, grew on both plates, since Gal4 is 
ligand independent, and RXRwt, purple arrow, did not grow on either plate since LG335 
is not a strong agonist for this receptor. 
5.2.4 Liquid Quantitation Assay  
For a more quantitative analysis, the variants that displayed ligand-activated 
growth at lower concentrations of LG335 were tested in liquid quantitation assays in 
chemical complementation. Yeast cells are transformed with both fusion proteins, GBD-
RXR and ACTR-GAD, and grown in liquid adenine selective media with and without 
ligand. The same CC concept described previously applies to adenine selective liquid 
media, when a ligand binds to the GBD-RXR, ACTR-GAD is recruited, turning on 
expression of the ADE2 gene. Yeast transformed with the RXR variants and ACTR-GAD 
were placed in 96-well plates with adenine-selective media (SC-ALW) and a range of 
ligand concentrations (Figure 5.8). Plates were incubated at 30
o
C with shaking, and 
optical density (OD) readings at the 630 nm wavelength were taken 0, 24, and 48 hours. 
Figure 5.9 shows results of the 23b variant tested in liquid quantitation assays 
with the synthetic ligand LG335 and the natural ligand 9cRA. The 23b variant was 
compared to the QCIMFI variant, RXRwt, and Gal4. Gal4 (green line) showed ligand-










Figure 5.7: Streaking Results of RXR Variants on Adenine Selective plates 
containing LG335: Streaking results of RXR variants on adenine selective (SC-ALW) 
plates without ligand and with LG335. Red circles are ligand-activated variants, yellow 









Figure 5.8: Liquid Quantitation Assay: Yeast transformed with RXR variants and 
ACTR-GAD are placed in 96-well plates with adenine selective media (SC-ALW) and a 
range of ligand concentrations. Plates are incubated at 30
o
C with shaking, and OD630 
readings are taken 0, 24, and 48 hours. Growth in wells indicates ligand activates 








displayed ligand-activated growth at 1 µM 9cRA (460 nM EC50 value) with a 8.7±0.5-
fold activation and no growth was observed in LG335. Interestingly, the 23b variant 
(purple line) showed reverse specificity, no growth was observed with 9cRA and growth 
was observed at 10 nM LG335 (4 nM EC50 value) with a 7.1±0.3-fold activation. This 
variant displayed increased sensitivity towards LG335 when compared to the QCIMFI 
variant that shows ligand-activated growth at 1 µM LG335 (300 nM EC50 value) with a 
7.0±0.5-fold activation. No growth was observed with QCIMFI in response to 9cRA. 
Two other variants (21b and 50b), which displayed ligand-activated growth on solid 
media, were also tested in liquid quantitation assays (data not shown), but were 
constitutively active. Therefore, the results from these libraries possibly show a new 
variant that is activated at a lower concentration of LG335. 
Several variants obtained from the nonselective and selective plates were 
sequenced. The sequencing of the nonselective variants determined the diversity and 
mutational limit of the error prone PCR method. The sequencing results shown in Table 
5.2 reveal the wide diversity of mutations in the nonselective variants. Most nonselective 
variants displayed one to two mutations at a variety of positions, showing the range of 
mutational space put through selection. Although a limited number of variants were 
submitted for sequencing, an increase in mutations was observed as the MnCl2 
concentration increased, as expected. Most selective variants did not display additional 
mutations beyond the parent plasmid, GRQCIMFI, except for the 21b and 23b variants.  
The sequencing results showed the additional mutation I324V produced a constitutively 
active variant in the case of 21b, but the L455M additional mutation produced a variant 




Figure 5.9: Ligand-Activated Growth Profiles of Gal4, RXRwt, QCIMFI, and 23b: 
Liquid quantitation assays in yeast with Gal4 (▲), RXRwt (●), variants 23b (♦), and 












a new variant, Q275C, I310M, F313I, and L455M (QCIMFILM) was discovered to bind 
and activate in response to LG335 with a 4 nM EC50 value. Also, the data shows that the 
epPCR method was successfully able to explore functional variants outside of the ligand 
binding pocket; however, the PCR conditions used were only able to create variants with 
one to two mutations. 
5.2.5 Activation Profile of the GRQCIMFILM Variant in Mammalian Cell Culture 
To confirm results observed in yeast, the quadruple variant (QCIMFILM) was 
then evaluated in mammalian cell culture assays for enhanced activity over the QCIMFI 
variant. The L455M mutation was added to the pMSCVGRQCIMFI plasmid via site-
directed mutagenesis and primers containing the L455M mutation. The new plasmid, 
pMSCVGRQCIMFILM, which constitutively expresses GRQCIMFILM, was 
cotransfected in the HEK293T cells with the p17*4TataLuc plasmid to test for luciferase 
activity. The p17*4TataLuc plasmid contains Gal4 response elements controlling 
expression of the report gene Renilla Luciferase.  
Results from the transfection (Figure 5.10) showed the new variant has a 10-fold 
increase in sensitivity towards the synthetic ligand LG335. QCIMFILM displays a 5 nM 
EC50 value, compared to the 50 nM EC50 value observed with QCIMFI. This data 
confirmed the results shown in yeast. The addition of the L455M mutation does increase 
the sensitivity of the receptor towards LG335; however, the increase is not as a drastic as 
the 100-fold increase observed in yeast. 
5.2.6 Libraries on the QCIMFILM variant 
 In an effort to further increase the sensitivity of the quadruple variant to LG335, 







Figure 5.10: Activation Profile of GRQCIMFI and GRQCIMFILM: Activation 
profiles in HEK293T cells transfected with GRQCIMFI (●) and GRQCIMFILM (■) in 




and various concentrations of MnCl2. The insert cassette was transformed into the PJ69-
4A strain with the linearized background plasmid (pGBDRXRBP) and the coactivator 
plasmid (pGAD10BAACTR), and then plated on nonselective plates and adenine 
selective plates with 100 nM and 10 nM LG335. Table 5.3 shows each library produced 
sufficient transformation efficiencies (~10
4
 cfu/ µg of DNA) and library sizes (~10
3
 
variants). Approximately 1% of each library was tested for constitutive activity, by 
streaking colonies on adenine selective plates without ligand and nonselective plates. As 
shown in Figure 5.11, most variants were constitutively active; however a few variants 
displayed slight growth on the adenine selective plate, and they were further evaluated in 
liquid quantitation assays. 
Variants were placed in adenine selective media with a range of ligand 
concentrations. Since the QCIMFILM variant is activated at 10 nM LG335, variants were 
evaluated at a lower concentration range to test for increased sensitivity towards LG335. 
As shown in Figure 5.12, no variants produced growth in response to 9cRA (Figure 
5.12A), and no variants display ligand-activated growth at lower concentrations than the 
quadruple variant (Figure 5.12B). The variants 2-36 (red line), 2-43 (brown line), and 2-
47 (black line) displayed ligand-activated growth at 100 nM LG335 (~50 nM EC50 value) 
with a ~9-fold activation, and no growth with 9cRA. The QCIMFILM variant displayed 
growth at 10 nM LG335 (6 nM EC50 value) with a 12.5±0.3-fold activation, and no 
growth with 9cRA. The controls RXRwt and Gal4 were consistent with previous 
experiments. Gal4 (green line) displayed growth regardless of the presence of ligand, and 
growth was observed with RXRwt (blue line) at 1 µM 9cRA (420 nM EC50 value) with a 























Figure 5.11: Streaking results for Constitutive Activity from QCIMFILM libraries: 
Streaking results of RXR variants from libraries 23a, 23b, and 23c on adenine selective 





Figure 5.12: Ligand-Activated Growth Profiles of Gal4, RXRwt, 2-36, 2-43, 2-47: 
Liquid quantitation assays in yeast with Gal4 (▲), RXRwt (●), variants 2-36 (+), 2-43 




variant, all variants displayed the parent plasmid sequence (Q275C, I310M, F313I, and 
L455M). This library shows that perhaps the mutational tolerance of this receptor has 
been reached. 
5.3 Determining the Role of the L455M Mutation 
When looking at the L455 position in the crystal structure of RXR, the residue is 
not located in the ligand binding pocket. In fact, this residue is approximately 9.31 Å 
away from the ligand (Figure 5.13). However, the L455 residue is in helix 12 (H12), a 
helix critical for receptor activation. As stated in Chapter 1, when an agonist binds to the 
receptor a conformational change takes place, especially in H12, allowing the recruitment 
of the coactivator complex. Structurally, the L455M mutation is a part of the AF-2 
domain, and does not directly interact with the ligand. However, previous findings have 
shown that this residue could also be involved in van der Waals interactions with 
surrounding residues.[21] Therefore, this mutation could increase the fold induction by 
stabilizing interactions in the ligand binding pocket, or by providing secondary 
interactions with coregulators for improved functionality of the receptor. To explore how 
the L455M mutation increased the activation of the receptor with LG335, the L455M 
position was added to single (Q275C, I310M, F313I), double (Q275C I310M, Q275C 
F313I, I310M F313I, and the triple (Q275C I310M F313I) variants, and tested for 
difference in receptor activation. The single, double, triple, and quadruple variants were 
created via site-directed mutagenesis into the pCMXRXRwt plasmid. The single, double, 
triple, and quadruple variants were then cotransfected into HEK293T cells with the 
pLuc_CRBPII plasmid. The pLuc_CRBPII plasmid contains RXR RE controlling 









Figure 5.13: Crystal structure of RXR bound to 9cRA: Crystal structure of RXR with 
residues in the ligand binding pocket (green) and the L455 residue (pink), which is 9.31 




Figure 5.14 shows the activation profiles of RXRwt and the single variants, 
Q275C and I310M, with and without the addition of L455M. A slight difference is 
observed in the activation profiles of RXRwt, Q275C, and I310M compared to when the 
L455M mutation is added. An increase in sensitivity with both ligands, 9cRA and 
LG335, is observed when the L455M is added to these variant. The EC50 value for 
RXRwt with 9cRA is 500 nM, and the addition of L455M showed slightly increases 
sensitivity with an EC50 value of 160 nM (Figure 5.14A). The same trend is observed 
with LG335 and the fold inductions with both ligands are comparable. A similar trend is 
observed with the addition of L455M to the Q275C and I310M variants. The Q275C and 
I310M displayed a 4,000 nM and 400 nM EC50 value, respectively, in response to 9cRA. 
However, the Q275C L455M and the I310M L445M showed increased sensitivity with 
9cRA, displaying a 790 nM and 200 nM EC50 value, respectively (Figure 5.14B and 
5.14C). The trend with increase in sensitivity was also observed when the same variants 
were tested with LG335.  
Interestingly, the F313I is activated at 100 nM LG335 (50 nM EC50 value) with a 
16±3-fold induction, and only displays a 5,000 nM EC50 value and 8±1-fold induction 
with 9cRA (Figure 5.15). Surprisingly, when L455M is added to the F313I variant, the 
receptor becomes constitutively active with no significant fold induction. 
When looking at the double variants, a more pronounced increased in activity 
with LG335 is observed (Figure 5.16). The EC50 value for the Q275C I310M variant with 
9cRA is greater than 10,000 nM and the fold induction is 10±2-fold; only a 2,000 nM 
EC50 value and 13±3-fold induction is observed in response to LG335. When the L455M 
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mutation is combined with the Q275C I310M variant, a 2-fold difference is seen in EC50 
value with LG335 (1,000 nM) and the fold induction increases to 20±3-fold.  
A similar trend is observed in Figure 5.17, when L455M is combined with the 
Q275C F313I variants. The Q275C F313I displays a 160 nM EC50 value and a 23±3-fold 
induction with LG335, and only a 11±2-fold induction with 9cRA. However, the Q275C 
F313I L455M variant has a 5-fold difference in the EC50 values when compared to the 
Q275C I310M variant with LG335.  
When L455M is added to the I310M F313I variant, a slight decrease in fold 
induction with LG335 is observed, whereas the EC50 values are very similar (Figure 
5.18). The I310M F313I is activated at 100 nM LG335 (80 nM EC50 value) with a 24±2-
fold induction and 10,000 nM 9cRA with a 10±5-fold induction. The I310M F313I 
L455M is activated at 100 nM LG335 (80 nM EC50 value) with a 15±4-fold induction, 
and 10,000 nM 9cRA with a 7±2-fold induction. 
When comparing the triple variant (Q275C I310M F313I) to the quadruple variant 
(Q275C I310M F313I L455M), a 2-fold difference is observed in the EC50 value with 
LG335. The triple variant has a 100 nM EC50 value and a 24±2-fold induction with 
LG335, while the quadruple variant has a 50 nM EC50 value and a 31±7-fold induction 
with LG335. Both variants show low activation with 9cRA. Table 5.4 provides a 
summary of the EC50 values and fold inductions of all the variants. From these activation 
profiles, the most appropriate variant for the molecular switch system is the quadruple 
variant (Q275C I310M F313I L455M), which displays the highest fold-induction and 










Figure 5.14: Activation Profiles of RXRwt, L455M, Q275C L455M, I310M, and 
I310M L455M: Activation profiles in HEK293T cells transfected with (A) RXRwt, 
L455M, (B) Q275C, Q275C L455M, (C) I310M, and I310M L455M in response to 9cRA 










Figure 5.15: Activation Profiles of F313I and F313I L455M: Activation profiles in 












Figure 5.16: Activation Profiles of Q275C I310M and Q275C I310M L455M: 
Activation profiles in HEK293T cells transfected with Q275C I310M and Q275C I310M 










Figure 5.17: Activation Profiles of Q275C F313I and Q275C F313I L455M: 
Activation profiles in HEK293T cells transfected with Q275C F313I and Q275C F313I 











Figure 5.18: Activation Profiles of I310M F313I and I310M F313I L455M: Activation 
profiles in HEK293T cells transfected with I310M F313I and I310M F313I L455M in 












Figure 5.19: Activation Profiles of Q275C I310M F313I and Q275C I310M F313I 
L455M: Activation profiles in HEK293T cells transfected with Q275C I310M F313I and 














chapter will examine the L455M mutation in more detail and how this mutation increases 
the fold-induction in the presence of LG335. 
5.4 Summary  
In summary, several processes were attempted to improve the molecular switch. The 
VP16 activation domain was fused to the N-terminus region of GRQCIMFI in an effort to 
increase the fold induction. However, the addition of the VP16 created a constitutively 
active protein, which would not be useful in the molecular switch system. The second 
approach used epPCR and chemical complementation to select for new variants with 
increases sensitivity towards LG335. This method produced a successful variant, Q275C, 
I310M, F313I, L455M (QCIMFILM), which displayed a 10-fold increase in sensitivity 
towards LG335 with a 50 nM EC50 value. Further mutagenesis on this variant did not 
increase sensitivity towards the ligand, suggesting that the mutational tolerance has been 
reached. Finally, the effect of L455M on the single, double and, triple, variants was 
explored for difference in activation. Overall, an increase in sensitivity with LG335 was 
observed when the L455M mutation was added. These results also confirmed that the 
most appropriate variant for the molecular switch system is the quadruple variant 
(QCIMFILM), since this variant has the lowest EC50 value and highest fold induction 
with LG335, and not activated by 9cRA.  
Several other approaches could be evaluated for further improvement in the 
molecular switch system. For instance, enhancer sequences, such as the chicken insulator 
sequence could be inserted into our molecular switch system to facilitate the expression 
of two genes simultaneously. More techniques could also be examined to optimize the 
viral titer, or an alternative viral vector could be used. Lastly another control should be 
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developed to test the effectiveness of dual expression in the same vector. The Gal4 DBD 
should be fused to the VP16 activation domain, which is a chimeric protein that would 
turn on expression of genes controlled by the Gal4 response elements without the 
addition of ligand. This fusion protein would replace GRQCIMFI and could be used for 
comparing inducible gene expression in transient transfections, as well as retroviral 
transductions.  
5.5 Materials and Methods 
Plasmid Construction 
The MfeI and AvrII the restriction sites were inserted into the pMSCVGRQCIMFI 
plasmid using the following primers: MfeIAvrIIfor, CCT TCT CTA GGC GCC GGA 
CAA TTG ATT CGT TAA CCT CGA GAG ATC TCC TAG GAT GAA GCT ACT 
GTC TTC TAT CGA ACA AG; and MfeIAvrIIrev, CTT GTT CGA TAG AAG ACA 
GTA GCT TCA TCC TAG GAG ATC TCT CGA GGT TAA CGA ATC AAT TGT 
CCG GCG CCT AGA GAA GG. The VP16 insert cassette was amplified from the 
pVP16 plasmid (a gift from the Ortlund lab, Emory University) using the following 
primers containing the MfeI or the AvrII restriction site: MfeIVP16for, AAA CAA TTG 
ACC ATG GGC CCT AAA AAG AAG; and VP16AvrIIrev, CTT CCT AGG GAA GCT 
TCT GCA GAC GCG TC. The insert cassette and the vector cassette was then digested 
with the MfeI and SacII restriction enzymes and ligated together using the Quick Ligase 
Enzyme (New England Biolab, Massachusetts). 
Mammalian Luciferase Assay 
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The pMSCV VP16-GRQCIMFI and the p17*4TataLuc plasmids were cotransfected at a 
1:2 molar ratio as described in Chapter 3. The single (Q275C, I310M, F313I, L455M), 
double (Q275C I310M, Q275C F313I, Q275C L455M, I310M F313I, I310M L455M, 
F313I L455M), triple (Q275C I3130M F313I, Q275C I310M L455M, Q275C F313I 
L455M, I310M F313I L455M), the triple (Q275C I310M F313I L455M) variants, and 
RXRwt were also cotransfected into HEK293T cells with the pLuc_CRBPII plasmid as 
previously described. 
Error prone PCR 
The RXR LBD gene was amplified from the pMSCVGRQCIMFI plasmid in a PCR using 
the following primers: Oligo1_For, GGA TCC TGG AGG CTG AGC TGG CCG TGG 
AGC CCA AGA CCG AGA CCT ACG TGG AGG CAA ACA TGG GGC TGA ACC 
CCA GCT CG; and Oligo 10_Rev, GGC CAG AAC GGG TGG GCA CAA AGG ATG 
GGC CCG CAG GCT TAA GCC TAA GTC ATT TGG TGC GGC GCC TCC AGC. 
The PCR solution also contained 10X Taq Buffer, dNTPs, MgCl2, 2, 20, or 200 µM 




 The insert cassette (1 µg) and 0.3 µg of the background plasmids pGBDRXRBP 
were transformed in the PJ69-4A strain using the TRAFCO yeast transformation 
protocol. The transformation mixture was placed onto nonselective plates (SC-LW) and 
adenine selective plates containing 100 nM LG335. Plates were incubated at 30
o
C for 3-4 
days. 
Liquid Quantitation Assay 
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Variants obtained from the yeast transformation were grown overnight in 
nonselective media SC-LW, at 30
o
C, shaking at 300 rpm. Variants were pelleted by 
centrifugation and resuspended in selective media SC-ALW with a range of ligand 
concentration and placed in 96-well plates. Plates were then incubated at 30
o
C, shaking at 
170 rpm for 48 hours. Optical density readings were taken at a 630 nm wavelength after 
0, 24, and 48 hours. 
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THE EFFECT OF L455 VARIANTS ON RECEPTOR ACTIVATION 
AND COACTIVATOR ASSOCIATION 
 
 
6.1 The Importance of H12 
The discovery of the QCIMFILM variant’s enhanced sensitivity towards LG335 
has prompted the further understanding of the L455 position. The L455 residue is located 
on helix 12 (H12), which plays a significant role in nuclear receptor (NR) function. When 
an agonist binds to a NR, H12 undergoes repositioning, allowing the association of 
coactivators [1, 2]. Besides the role H12 plays in coactivator association, the active 
conformation of H12 has been shown to be stabilized by residues in the ligand binding 
pocket (LBP) [3, 4].   
The activation function 2 (AF-2) core found in H12 is a highly conserved motif 
throughout the nuclear receptor superfamily [5]. Mutational analysis has been performed 
at each of the positions in the AF-2 core of RXR to understand the impact of each residue 
on receptor activity and coregulator interactions. As shown in Figure 6.1, one key residue 
in this helix is the highly conserved glutamic acid (E), which clamps the coactivator to 
the receptor through electrostatic and dispersion interactions [6-9]. Electrostatic 
interactions occur between two oppositely charged molecules, whereas dispersion forces 
are weak attractive forces, which cause instantaneous polarization of a molecule. 
Conserved mutations at this position can completely abolish coactivator association; thus, 
eliminating receptor activity [10].  
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The L455 residue, which is well conserved within the retinoid receptors, has been 
shown not to eliminate coactivator association when mutated to an alanine. However, 
previous data has shown that substituting an alanine at this position decreases activation 
and enhances the receptor’s interaction with corepressors [4, 11-13].   
In Chapter 5, the addition of the L455M mutation to RXR variants led to 
increased activation with a novel small molecule, LG335. The quadruple variant 
(QCIMFILM) displayed a 10-fold increase in sensitivity towards LG335 (50 nM EC50 
value) and a 31±7-fold induction. The single variant L455M also showed a slight increase 
in sensitivity toward LG335 (200 nM EC50 value and a 15±2-fold induction) when 
compared to RXRwt (630 nM EC50 value with a 10±3-fold induction). Since the L455 
position is located approximately 9 Å away from the ligand, and is on a helix known to 
associate with other proteins, initial thoughts were that this residue is involved in 
coactivator or corepressor association. However, the data from Chapter 5 also led to the 
consideration that this residue indirectly influences ligand binding. When L455M was 
added to some of the variants tested an increase in activation with LG335 was observed. 
For instance, when L455M was added to the Q275C F313I variant the EC50 value was 
reduced by 5-fold. Also, the addition of the L455M mutation to the F313I variant 
produced a constitutively active receptor. These results and the location of L455 
suggested that this residue perhaps interacts indirectly with the ligand through an 
allosteric mechanism affecting other residues in the ligand binding pocket (LBP). Two 
hypotheses were investigated in this chapter. First, the involvement of L455 with 








Figure 6.1: Sequence Alignment of H12 in Nuclear Receptor: Sequence alignment of 
helix 12 of select nuclear receptors. Highlighted in yellow are the highly conserved 




The role of L455 in coactivator association was also assessed in yeast with two known 
coactivators to determine whether the activity of the variant differs from one coactivator 
to the other. The tolerance at this position was also assessed to determine if other 
mutations at that position could modify receptor activity, and perhaps lead to a molecular 
switch with enhanced activity with various ligands. 
6.2 Tolerance at the L455 position 
6.2.1 Testing L455 Variants in Chemical Complementation 
To evaluate the receptor’s tolerance for mutations at the L455 position, the 
residue was mutated to ten amino acids via site-directed mutagenesis with primers 
containing mutations at the L455 position. The amino acids that were chosen (alanine, 
cysteine, phenylalanine, histidine, lysine, methionine, serine, threonine, valine, and 
tyrosine) represent all classes of amino acids. The volume of the amino acids ranged from 
alanine (88.6 Å
3
) to tyrosine (193.6Å
3
) [14], allowing the evaluation of the minimal and 
maximal space this reside can occupy without compromising receptor function. Each 
category of amino acids was also selected based on their chemical properties, such as 
hydrophobic, charged, and polar. These variants were first tested in yeast via chemical 
complementation (CC). 
As stated in Chapter 5, CC is a genetic selection system that links the binding and 
activation of a nuclear receptor by a small molecule to the survival of yeast [15]. This 
selection system is a three-component system consisting of a Gal4 DNA DBD fused to 
the RXR LBD (GBD-RXR), a coactivator fused to the Gal4 activation domain (CoAc-
GAD), and a small molecule. Gal4 is a yeast transcription factor that is ligand 
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independent [16]. When a ligand binds to GBD-RXR, a conformation change takes place, 
allowing the recruitment of CoAc-GAD, leading to the expression of an essential gene. 
RXR variants subjected to chemical complementation are grown on media lacking the 
essential nutrient adenine, but have the desired small molecule, 9cRA or LG335. Only 
functional variants that can be activated by the ligand should grow in the adenine 
selective media (ligand-activated growth). 
Figure 6.2 shows L455 variants tested in liquid quantitation assays containing 
adenine selective media in response to either a range of 9cRA or LG335. All variants 
showed decreased ligand-activated growth compared to the wild-type receptor, except the 
L455M variant. RXRwt (blue circles) displayed an EC50 value of 43 nM with a 10-fold 
activation with 9cRA, and no ligand-activated growth was observed with LG335. As 
expected, changing L455 to the charged residues, histidine (green circles) and lysine 
(pink squares), produced no ligand-activated growth in response to 9cRA or LG335 
(EC50 values is greater than 10,000 nM and a 1-fold activation was observed). The same 
result was observed with the smallest and largest hydrophobic residues, alanine (red 
triangles) and phenylalanine (green diamonds), indicating that the volume of the residue 
is important. The L455V variant (brown stars) that is slightly smaller than the wild type 
residue showed ligand-activated growth, but at higher concentrations of 9cRA than the 
wild type receptor (240 nM EC50 value), and no growth was observed with LG335. The 
growth observed with L455V showed that hydrophobic residues that occupy similar 
volume to leucine are tolerated at this position.  
Interestingly, the polar residues, L455S and L455T, showed growth with both 








Figure 6.2: Ligand-Activated Growth Profiles of L455 Variants: Gal4, RXRwt, and 
L455 variants tested in liquid quantitation assays in adenine selective media (SC-ALW) 




and a 5-fold activation with 9cRA. The EC50 value with LG355 was greater than 10,000 
nM and a 9-fold activation was detected. The L455T variant (gold diamonds) showed a 
79 nM EC50 value and an 8-fold activation with 9cRA. Again, the EC50 value was greater 
than 10,000 nM, and a 6-fold activation was detected. The large polar residue, L455Y 
(gold lines), did not show ligand-activated growth with either ligands. These results show 
that polar residues are tolerated at this position; however, the residue must occupy a 
certain amount of space. 
The L455C (green downward triangle) also showed ligand activated growth in 
response to 9cRA, displaying a 340 nM EC50 value and a 9-fold activation. No growth 
was observed with LG335. Again, this result shows that the cysteine residue is tolerated 
at this position, but wild type receptor function is not achieved. As shown in Chapter 5, 
the L455M variant (black open triangle) displayed a similar growth profile with 9cRA as 
the wild type receptor, displaying a 31 nM EC50 value and a 10-fold activation. Also, 
ligand-activated growth was observed at 1 μM LG335 (250 nM EC50 value) with a 9-fold 
activation. Table 6.1 is a list of EC50 values and fold activations of all variants in the 
chemical complementation system.  
These results indicate that tolerance is observed at the L455 position with 
hydrophobic and polar residues with limitations in the volume. Only the L455M variant 
displayed activity comparable to the wild type receptor. No other variants were able to 
enhance receptor activation with 9cRA, but three variants, L455M, L455S, and L455T, 
were able to show enhanced activity with LG335. Volume seems to be of particular 
















Both hydrophobic and polar residues are tolerated at this position, as seen with L455T 
and L455V. 
6.2.2 Testing L455 Variants in Mammalian Cell Culture 
To verify the results observed in yeast, L455 variants were tested in mammalian 
cell culture assays. Each variant was made via site-directed mutagenesis on the 
pCMXRXRwt plasmid. As stated in Chapter 5, the pCMXRXRwt plasmid is a 
mammalian vector that constitutively expresses full length RXRwt under control of the 
CMV promoter. The single variants were then tested in a luciferase assay with the natural 
ligand, 9cRA, and the synthetic ligand LG335. HEK293T cells were cotransfected with 
the L455 variants along with the reporter plasmid, pLuc_CRBPII at a 1:2 molar ratio. The 
pLuc_CRBPII plasmid contains RXR response elements (RE) controlling expression of 
the reporter gene Renilla luciferase. RXRwt was also tested alongside as a positive 
control. 
As shown in Figure 6.3, most of the variants did not display enhanced activation 
in comparison to the wild type receptor, confirming results seen in yeast. RXRwt (purple 
circle) is activated at 1µM 9cRA with a 400 nM EC50 value and a 31±9-fold induction. 
RXRwt shows decreased activation with LG335 having only a 12±4-fold induction and a 
540 nM EC50 value. When L455 was mutated to charged or large aromatic residues, 
histidine (green diamonds), lysine (green circles), phenylalanine (yellow downward 
triangles), and tyrosine (gold diamonds), activation was completely abolished. On the 
other hand, the polar residues, serine (pink squares) and threonine (blue open triangle), 







Figure 6.3: Activation Profiles of L455 Variants in Cell Culture” Activation profiles in 
HEK293T cells transfected with RXRwt, L455A, L455C, L455F, L455H, L455K, 
L455S, L455T, L455V, and L455Y in response to 9cRA or LG335.   
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decreased, displaying a 14±3 and 17±6-fold induction, respectively. Alanine (black 
squares), a smaller hydrophobic amino acid, did not show ligand-activated growth in 
yeast, and decreased activation was observed in mammalian cell with a 13±6-fold 
induction and 630 nM EC50 value. The cysteine and the valine residues showed the most 
comparable results to the wild type receptor, also seen in yeast. The cysteine residue (red 
triangles) displayed a 23±6-fold induction and 580 nM EC50 value in response to 9cRA, 
and valine (purple downward triangles) showed a 17±6-fold induction and 130 nM EC50 
value with 9cRA. Table 6.2 list the EC50 values and fold activations of all variants with 
9cRA and LG335.  
As shown in Figure 6.4, the L455M variant shows slightly increases sensitivity 
towards the natural ligand 9cRA, as well as, the synthetic ligand LG335, displaying a 
22±3-fold induction and 150 nM EC50 value in the presence of 9cRA (pink downward 
triangles), and 13±3-fold induction and 120 nM EC50 value with LG335 (green diamonds 
shown in Figure 6.4). The methionine and leucine residue are similar since they both 
display hydrophobic properties, and the fact that their volume is approximately the same 
(~165 Å
3
) could explain the similarities in the activation profiles.  
Overall, the yeast assays and the luciferase assays evaluated the amino acid 
tolerance at the L455 residue. The data reveals that this residue is fairly tolerable, since 
five out of the ten variants displayed considerable growth or activation. However, 
activation is not comparable to the wild type receptor with most of the variants. Charged 
residues (histidine and lysine) and the residues with the largest volume (phenylalanine 
and tyrosine) are not tolerated at this position, but the hydrophobic residues with 










Figure 6.4: Activation Profiles of L455M Variants in Cell Culture: Activation profiles 
in HEK293T cells transfected with RXRwt and the L455M variants in response to 9cRA 










The most surprising piece of data is that polar residues showed significant activation, 
indicating that the conserved hydrophobic nature of this residue could be changed such 
that activation profiles similar to the wild type receptor are achieved.  
6.3 Assessment of the Double Variants L436V L455 and L436F L455 
6.3.1 Testing of Double Variants in Chemical Complementation 
Recently, RXR crystal structures have been obtained with new ligands that have a 
mixture of agonist and antagonist properties, also known as nuclear receptor selective 
modulators. The analysis of these crystal structures showed the antagonistic properties of 
a ligand depends on the orientation of the L436 residue. Several studies have proposed 
that L436, a residue in the LBP of RXR, stabilizes H12 through van der Waals interaction 
with the L455 residue when a ligand binds [4, 17]. Ligands able to push L436 closer to 
L455 showed more antagonistic characteristics, due to steric interference with L455, 
causing the destabilization of H12 [18, 19]. Previously, Peet et al. have shown that 
mutating L436 to a valine, a smaller hydrophobic residue, severely decreases receptor 
activation [20]. The proposed reason for lost in activation was due to the fact that the 
L436V residue in the holo confirmation cannot effectively stabilize H12 since the 
interaction with the L455 residue is lost. 
To further evaluate the effects of the L455 variants on receptor activity, these 
variants were tested in combination with the L436V residue, known to drastically reduce 
receptor activity. The idea was to investigate whether the L455M mutation (as well as 
other L455 mutations) could compensate for the lack of activation observed with the 
L436V mutation. The L436V mutation was added the L455 variants (L455A, L455C, 
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L455F, L455H, L455K, L455M, L455S, L455T, L455V, and L455Y) and RXRwt via 
site-directed mutagenesis. Primers containing the modified residue were used with the 
pGBDRXR plasmids to create the double variants of L436V L455, as well as the L436V 
single variant. The variants were then transformed into the PJ69-4A strain, grown on 
nonselective plates, and tested in ligand quantitation assays in adenine-selective media 
with a range of 9cRA and LG335 concentrations.  As described in Chapter 3, in liquid 
quantitation assays, variants transformed into the PJ69-4A strain with the coactivator 
plasmid (pGAD10BAACTR) are place in 96-well plates with adenine selective media 
with various concentrations of ligand and are incubated at 30
o
C with shaking. Optical 
density (OD) readings are taken at 630 nm at 0, 24, and 48 hours. 
Figure 6.5 shows that the L436V single variant (brown squares) displayed no 
ligand-activated growth with either 9cRA or LG335, as expected, since this mutation was 
known to severely lower receptor activity [20]. Also, ligand-activated growth was not 
observed with any of the double variants in response to either ligand. The double variants 
are composed of the L436V mutation and one of the L455 mutations. The controls, Gal4 
(green line) and RXRwt (blue circles) showed growth as expected. Gal4 grows regardless 
of the presence of ligand in the adenine selective media. RXRwt showed ligand-activated 
growth at 100 nM 9cRA (74 nM EC50 value) with a 9-fold induction, and no growth with 
LG335, as observed in several other data sets. Therefore, the data shows that none of the 
L455 variants were able to compensate for the loss of activation when then the L436V 
mutation is introduced. 
Since the L436V variant is known to severely decrease receptor activity, perhaps 








Figure 6.5: Ligand-Activated Growth Profiles of L436V L455 Variants: Gal4, 
RXRwt, L436V, L436VL455A, L436VL455C, L436VL455F, L436VL455H, 
L436VL455M, L436VL455S, L436VL455AT, L436VL455V, and L436VL455Y tested 





activation. Thus, the L436F mutation, which is also known to reduce receptor activity but 
not as drastically as the L436V mutation, was also tested. Again, the idea was that 
perhaps one of the L455 mutations could compensate for a slight loss of activity [20]. 
The L436F mutation was added to the L455 variants via site-directed mutagenesis. 
Variants were then transformed into the PJ69-4A strain, grown on nonselective plates, 
and tested in liquid quantitation assays in adenine-selective media with a range of 9cRA 
and LG335 concentrations as described above.  
Figure 6.6 shows the single variant, L436F (brown square), with decreased 
ligand-activated growth, as expected, displaying growth at 1 µM 9cRA (760 nM EC50 
value) with a 10-fold activation, and no growth with LG335. However, no growth was 
also observed with any of the double variants with either ligand. Again, Gal4 (green 
lines) showed growth independent of ligand, and RXRwt (blue circles) showed growth at 
100 nM 9cRA (40 nM EC50 value) with a 11-fold activation, and no growth with LG335. 
The results above show none of the double variants tested, L436V L455 or the L436F 
L455, were functional, indicating that the L455 mutations could not compensate for the 
loss of activation observed with the L436 variants. In fact, the addition of the L455 
variants further destabilized the receptor, since all double variants displayed no ligand-
activated growth.  
6.3.2 Testing of Double Variants in Mammalian Cell Culture 
 To confirm the results observed in yeast, a subset of L436V L455 variants were 
evaluated in mammalian cell assays. The double variants were created by adding the 
L436V mutation to the L455 variants on the pCMXRXRwt plasmids using site-directed 







Figure 6.6: Ligand-Activated Growth Profiles of L436F L455 Variants: Gal4, 
RXRwt, L436F, L436FL455A, L436FL455C, L436FL455F, L436FL455H, 
L436FL455K, L436FL455M, L436FL455S, L436FL455T, and L436FL455Y tested in 





L436VL455M, the single variants, L436V and L455M, and RXRwt were cotransfected 
with the pLuc_CRBPII plasmid at a 1:2 molar ratio into HEK293T cells.  
As shown in Figure 6.7, the L436V variant (purple squares) reduces the 
sensitivity and the function of the receptor with a 100-fold decrease in sensitivity towards 
9cRA (EC50 value >10 μM) and barely any activation with a 6±2-fold induction. The 
L436V variant also showed decrease activity with the synthetic ligand, LG335, 
displaying a 1.7 µM EC50 value and a 5±1-fold induction. The L455M variant showed 
enhanced activation, as expected, displaying a 180 nM EC50 value and a 16±1-fold 
induction with 9cRA, and a 220 nM EC value and a 13±3-fold induction in response to 
LG335. The double variant, L436V L455M (green diamonds), showed an EC50 value 
slightly lower than RXRwt. This variant displayed a100 nM EC50 value in the presence of 
9cRA (Figure 6.7), but with only 8±0.4-fold induction, significantly lower than wild type 
receptor. RXRwt displayed a 410 nM EC50 value and 25±3-fold activation in response to 
9cRA. Interestingly, the double variant has a 10-fold increase in sensitivity towards 
LG335; a 90 nM EC50 value was observed with L436VL455M compared to the 910 nM 
EC50 value observed with RXRwt. The double variant also showed a 17±3-fold induction 
with LG335, comparable to RXRwt, which has a 14±4-fold induction. Also a lower EC50 
values and similar fold activation was observe when comparing the double variant to 
RXRwt in the presence of LG335. Therefore, the L436VL455M variant restores 
activation of the receptor with lower EC50 values when compared to the L436V variant.  
Two other variants were also evaluated for luciferase activity, L436V L455S and 
L436V L455T. Again, these variants were created by adding the L436V mutation to the 
pCMXRXRL455S and pCMXRXRL455T plasmids via site-directed PCR. The single 
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variants, the double variants, and RXRwt were cotransfected into HEK293T cells with 
pLuc_CRBPII at a 1:2 molar ratio with a range of 9cRA. The activation profile of the 
L436V variant again showed an undectectable EC50 value and a low fold induction of 
7±1-fold induction. As shown in Figure 6.8A, the single variant L455S has a 400 nM 
EC50 value with a 9±2-fold induction in response to 9cRA. When the L436V mutation is 
added to this variant, the receptor becomes practically nonfunctional, displaying a 3±2-
fold induction. Therefore, the combination of the L455S and L436V leads to an inactive 
receptor. 
When looking at the L436V L455T variant, a slight increase in sensitivity towards 
9cRA and a higher fold induction is observed in comparison to the L436V variant (Figure 
6.8B). The L436V L455T variant displays a 29 µM EC50 value and a 10±1-fold induction 
in response to 9cRA. However, the activation is not comparable to the single variant 
L455T or RXRwt. The L455T variant displays a 480 nM EC50 value with a 19±3-fold 
induction, while RXRwt displays a 410 nM EC50 value and a 14±2-fold induction. 
Therefore, this variant is able to slightly compensate for the L436V mutation, but 
activation is not restored to wild type.  
Our studies confirm that L436 is important for receptor activation and that the 
interaction of L436 and L455 is also crucial.  The L455M variant is able to compensate 
for the loss of function when added to the L436V variant with 9cRA, and enhanced 
activation in the presence of LG335 is also observed. The L436V L455S double variant 
showed complete loss of activity; however, the L436V L455T double variant was able to 
show slightly enhanced activation over the L436V variant, but activation was still 








Figure 6.7: Activation Profiles of L436V L455M in Cell Culture: Activation profiles in 
HEK293T cells transfected with RXRwt, L436V, L455M, and L436VL455M in response 











Figure 6.8 Activation Profiles of L436V L455S and L436V L455T in Cell Culture: 
Activation profiles in HEK293T cells transfected with RXRwt, L436V, (A) L455S, 
L436V L455S, (B) L455T, and L436V L455T in response to 9cRA:   
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6.4 Ligand-Activated Growth Profiles of L455 Variants with SRC-1 and ACTR 
As stated at the beginning of this chapter, once an agonist binds to the receptor, a 
conformational change takes place allowing coactivators to bind to the receptor for the 
initiation of transcription. The positioning of the AF-2 domain is crucial for coregulator 
interactions. An example of coregulators include the p160 steroid receptor coactivator 
(SRC) family, which directly interact with nuclear receptors, as well as, forms protein 
complexes with other factors that remodel chromatin or interact with general 
transcription factors. Therefore, these proteins provide a sophisticated process for gene 
regulation. Three members of the SRC family have been identified based on homology: 
SRC-1 (also known as NCoA-1), SRC-2 (also known as GRIP1, TIF2, or NCoA-2) and 
SRC-3 (also known as ACTR, p/CIP, RAC3, AIB1, TRAM-1) [21].  These coactivators 
are expressed in several types of tissues. The overexpression of the SRC proteins has 
been implicated in various cancers [21, 22], such as breast, ovarian and prostate cancer 
[23-26]. Therefore, several studies have investigated the interaction of coactivators with 
NR. Complete removal of the RXR AF-2 and mutational analysis on residues within this 
domain has lead to enhanced corepressor association and disassociation of coactivators 
[11, 27].  
In relation to specific residues in RXR AF-2, the L455 residue has been mutated 
to an alanine, and a stronger association with corepressors was observed, correlating this 
residue to the functionality of H12 [11, 12]. H12 also plays an important role in inhibiting 
corepressor binding for RXR. The tetramer formed by RXR in the absence of ligand is 
partly due to the factor that H12 can bind to the corepressor binding site on an adjunct 
monomer, silencing the receptor [28, 29].  
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One of the proposed reasons why the L455M variant has increased sensitivity 
towards LG335 could be due to the enhanced interaction with coactivators. To investigate 
whether the different coactivators display various growth profiles, chemical 
complementation (CC) was used. CC provides the advantage of using yeast based assay, 
free of interference from endogenous receptors and coactivators seen in mammalian cells. 
Yeast are simple eukaryotes that have the essential transcription machinery, similar to 
mammalian cell, but lack nuclear receptors and certain coactivators [30, 31]. Therefore, 
this system is suitable for examining interaction of the RXR variants with known 
coactivators, since specific NR and coactivators can be introduced and analyzed without 
the possibility of interference from other proteins.  
RXR variants subjected to chemical complementation were first transformed in 
the PJ69-4A strain with either SRC-1 or ACTR (activator for thyroid hormone and 
retinoid receptor, also known as SRC-3) and grown on nonselective media plates. 
Variants were then tested in liquid quantitation assays with media lacking the essential 
nutrient adenine, but have the desired small molecule 9cRA or LG335. Only functional 
variants that can be activated by the ligand and associate with the coactivator should 
grow in the adenine selective media. 
As shown in Figure 6.9, the positive control full length Gal4, a ligand independent 
transcription factor [32], showed growth regardless of ligand or coactivator, as expected. 
Growth was observed for RXRwt at 100 nM 9cRA (~40 nM EC50 value) regardless of 
which coactivator was present with approximately a 10-fold activation and no growth 
was observed with LG335. The single variants (Figure 6.10), L455A, L455F, L455H, 










Figure 6.9: Ligand-Activated Growth Profiles in Gal4 and RXRwt with ACTR and 
SRC-1: Gal4 and RXRwt tested in liquid quantitation in adenine selective media (SC-




LG335) or coactivator (ACTR or SRC-1). These results were expected due to the factor 
that these variants either show no or very little activation in cell culture.  
Some variants did not have a preference for either coactivator, as shown in Figure 
6.11. The L455C variant is activated at 1 μM 9cRA with both coactivators with a 9-fold 
activation, and no growth is observed with LG335 (Figure 6.11A). The single variant 
L455T also shows no preference for either coactivator displaying ligand-activated growth 
at 100 nM 9cRA (~30 nM EC50 value) (Figure 6.11B), and displayed growth at 10 μM 
LG335 with this variant (EC50 value >10 µM).  
The L455V variant exhibits a slight preference for the ACTR coactivator over the 
SRC-1 coactivator; a lower EC50 value (48 nM) and higher fold activation (9-fold) was 
observed with ACTR than with SRC-1 (150 nM EC50 value and 7-fold activation was 
observed with SRC-1) (Figure 6.11C). One of the most significant differences was 
observed with the L455S variant, which displayed growth at 1 µM 9cRA with ACTR, 
and growth was also observed at 10 µM LG335 (EC50 value >10µM) (Figure 6.12) . No 
growth was observed with either ligand when L455S was tested with the SRC-1 
coactivator.  
Another significant difference was observed with the L455M variant. Ligand-
activated growth was observed at 10 nM 9cRA (33 nM EC50 value), and at 1 µM LG335 
(344 nM EC50 value) with the ACTR coactivator. However this variant is constitutively 
active with the SRC-1 coactivator (Figure 6.13). The enhanced interaction of the L455M 
variant with SRC-1 might explain the enhanced activity observed in mammalian cells. 
Table 6.3 is a list of EC50 values and fold-activations of the L455 variants with ACTR 








Figure 6.10: Ligand-Activated Growth Profiles of L455A, L455F, L455H, L455K,and 
L455Y with ACTR and SRC-1: (A) L455A, (B) L455F, (C) L455H,  (D) L455K, and 
(E) L455Y tested in liquid quantitation in adenine selective media (SC-ALW) with a 




























































































● L455A + ACTR + 9cRA
 L455A + SRC1+ 9cRA
 L455A + ACTR + LG335
 L455A + SRC1 + LG335
● L455F + ACTR + 9cRA
 L455F + SRC1+ 9cRA
 L455F + ACTR + LG335
 L455F + SRC1 + LG335
● L455H + ACTR + 9cRA
 L455H + SRC1+ 9cRA
 L455H + ACTR + LG335
 L455H + SRC1 + LG335
● L455K + ACTR + 9cRA
 L455K + SRC1+ 9cRA
 L455K + ACTR + LG335
 L455K + SRC1 + LG335
● L455Y + ACTR + 9cRA
 L455Y + SRC1+ 9cRA
 L455Y + ACTR + LG335














Figure 6.11: Ligand-Activated Growth Profiles of L455C, L455T, and L455V with 
ACTR and SRC-1: L455C, L455T, and L455V tested in liquid quantitation in adenine 
selective media (SC-ALW) with a range of 9cRA or LG335 and either the ACTR or the 













Figure 6.12: Ligand-Activated Growth Profiles of L455S with ACTR and SRC-1: 
L455S tested in liquid quantitation in adenine selective media (SC-ALW) with a range of 













Figure 6.13: Ligand-Activated Growth Profiles of L455M with ACTR and SRC-1: 
L455M tested in liquid quantitation in adenine selective media (SC-ALW) with a range 














These results indicate that the mutations at the L455 position could potentially 
have an effect in selecting RXR’s preference for different coactivators, such as in the 
case of the L455S variant, which shows a preference for ACTR in comparison to SRC-1. 
Surprisingly, the L455M variant is constitutively active with the SRC-1 coactivator, 
possibly the reason why enhanced activation is observed with this variant in cell culture. 
This study confirms the role of L455 in stabilizing the interaction of the receptor with 
their coregulators. 
6.5 Ligand-Activated Growth Profiles of Double Variants with SRC-1 and 
ACTR 
A subset of double variants was also tested in chemical complementation with 
both coactivators. As controls, the single variants with mutations inside the ligand 
binding pocket, L436V and L436F, were also evaluated. The single variants (L436V and 
L436F) and a subset of double variants were transformed into the PJ69-4A strain with 
either ACTR or SRC-1 fused to the Gal4 activation domain (GAD) and grown on 
nonselective plates containing nonselective media. Variants were then tested in liquid 
quantitation assays in adenine selective media with either 9cRA or LG335. 
The single variants, shown in Figure 6.14, had the same ligand-activated growth 
profile with both coactivators. The L436V variant showed no growth with either 
coactivator or ligand, and the L436F variant showed growth at 1 µM 9cRA with both 
coactivators and no growth with LG335. 
As expected, when evaluating the double variants L436VL455A and 
L436FL455A (Figure 6.15), no ligand activated growth was observed with either ligand 









Figure 6.14: Ligand-Activated Growth Profiles of L436V and L436F with ACTR and 
SRC-1: L436V and L436F tested in liquid quantitation in adenine selective media (SC-






































Figure 6.15: Ligand-Activated Growth Profiles of L436V L455A and L435F L455A 
with ACTR and SRC-1: (A) L436V L455A and (B) L436FL455A tested in liquid 
quantitation in adenine selective media (SC-ALW) with a range of 9cRA or LG335 and 







activity. As shown in Figure 6.16A, the double variant, L436VL455M, showed no 
growth with ACTR; however, growth is observed at 1 µM 9cRA (3 µM EC50 value) and 
a 6-fold activation with the SRC-1 coactivator. Unfortunately, no growth is observed with 
either coactivator in response to LG335, which contradicts the cell culture data displayed 
in Figure 6.7, where the L436VL455M has the best activity in response to LG335. Since 
only two coactivators were tested this could be due to the association of this variant with 
other coactivators in the cells, or decreases interaction with corepressors. Also, the 
L436FL455M variant showed no growth with either coactivator or ligand (Figure 6.16B). 
Interestingly, Figure 6.17 shows the L436VL455T variant preferred the SRC-1 
coactivator, which was surprising since the single variant, L455T, did not have a 
preference for either coactivator. The L436VL455T variant showed ligand-activated 
growth at 1 µM 9cRA (400 nM EC50 value) and a 7-fold activation with SRC-1 and 10 
µM 9cRA (EC50 value >10 µM) and a 6-fold activation with ACTR (Figure 6.17A). The 
preference for the SRC-1 coactivator is also seen with the L436FL455T variants (Figure 
6.17B), displaying a 290 nM EC50 value and a 7-fold activation with 9cRA. The 
L436FL455T variant showed a 1.9 μM EC50 value and a 5-fold activation with the ACTR 
coactivator. Both the L436VL455T and the L436FL455T show no growth with the either 
coactivator in response to LG335. The preference for the SRC-1 coactivator was also 
seen in the L436VL455V and L436FL455V variants (Figure 6.18). The L436VL455V 
variant showed ligand-activated growth at 10 μM 9cRA (EC50 value >10 µM) with a 4-
fold activation with SRC-1(Figure 6.18A). The L436FL455V variant displayed a 300 nM 












Figure 6.16: Ligand-Activated Growth Profiles of L436V L455M and L436F L455M 
with ACTR and SRC-1: (A) L436VL455M and (B) L436FL455M tested in liquid 
quantitation in adenine selective media (SC-ALW) with a range of 9cRA or LG335 and 













Figure 6.17: Ligand-Activated Growth Profiles of L436V L455T and L436F L455T 
with ACTR and SRC-1: (A) L436VL455T and (B) L436FL455T tested in liquid 
quantitation in adenine selective media (SC-ALW) with a range of 9cRA or LG335 and 








Figure 6.18: Ligand-Activated Growth Profiles of L436V L455V and L436F L455V 
with ACTR and SRC-1: (A) L436VL455V and (B) L436FL455V tested in liquid 
quantitation in adenine selective media (SC-ALW) with a range of 9cRA or LG335 and 









Figure 6.19: Ligand-Activated Growth Profiles of L436V L455S and L436F L455S 
with ACTR and SRC-1: (A) L436VL455S and (B) L436FL455S tested in liquid 
quantitation in adenine selective media (SC-ALW) with a range of 9cRA or LG335 and 













only showing a 3-fold activation with the ACTR coactivator. The L436VL455V and 
L436FL455V variants showed no growth in response to LG335 with both coactivators.  
Lastly, the L436VL455S variant showed no growth with either coactivator (Figure 6.19). 
This was not surprising since the previous results showed the single variant, L455S had a 
preference for ACTR, and most double variants did not displayed ligand-activated growth 
with the ACTR coactivator. 
The data also shows that mutations within the ligand binding pocket do not 
exhibit a preference for either coactivator. The single variants, L455T and L455V, 
showed no preference for a coactivator; however, in the combination with the L436V or 
the L436F mutations, these double variants displayed a more pronounced preference to 
the SRC-1 coactivator. Interestingly, the L455M variant was found to be constitutively 
active with the SRC-1 coactivator, but ligand activation was observed when the L436V 
mutation was added to L455M at 1 µM 9cRA. This data also infers that the L436 residue 
is directly affected by the presence of the L455 residue, since specific mutations at this 
position ultimately affect the association of the receptor and the coactivator. Overall, this 
data confirms that the L455 position is crucial for coactivator interactions.  
In summary, this chapter looks into the importance of the L455 position and 
understanding the affect this residue has on the activity of RXR. First, the L455 position 
was mutated to several amino acids to analyze the tolerance at this position. Results from 
this section show that hydrophobic and polar residues that are similar in volume to 
leucine, displayed activation profiles comparable to RXRwt.  The L455 variants were 
then analyzed with various L436 mutations to determine if one of the L455 mutations 
could rescue a nonfunctional variant. The results from this section showed that the 
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L436V L455M mutation could restore receptor activity, especially with LG335. Lastly, 
the interaction with the ACTR and the SRC-1 coactivators were examined in chemical 
complementation, where the L455 residue was shown to impact coactivator interaction 
with the receptor.  
6.6 Materials and Methods 
Plasmid Construct 
 The L455 mutations (L455A, L455C, L455F, L455H, L455K, L455M, L455S, 
L455T, L455V, and L455Y) were added to pGBDRXR and pCMXRXRwt plasmid by 
subjecting plasmids to site-directed mutagenesis with primers containing the appropriate 
mutation. The L436V and the L436F mutations were added to the single pGBDRXR and 
pCMXRXR plasmids using site-directed mutagenesis and primers containing either 
L436V or L436F mutation. 
Liquid quantitation assays 
 The single and double variants were tested in liquid quantitation assays by 
transforming the variants and the coactivator plasmid (pGAD10BAACTR or 
pGAD10BASRC1) into the PJ69-4A strain, and grown overnight in nonselective media 
(SC-LW) at 30
o
C with shaking at 300 rpm. Then testing in adenine selective media as 
described in chapter 5. 
Mammalian Cell Culture assays  
The single and double variants were tested in cell culture assays by cotransfecting 
HEK293T cell with the pCMXRXR plasmid with the respective mutation and the 
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pLuc_CRBPII plasmid at a 1:2 molar ratio. The transfection and the assessment for 
luciferase and β-galactosidase activity are described in Chapter 3. 
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CONCLUSIONS AND FUTURE WORK 
 
7.1  The Molecular Switch System 
7.1.1 Conclusions 
Two orthogonal ligand receptor pairs (OLRP) were characterized as molecular 
switches to provide controlled gene expression and potentially benefit gene therapy 
applications. One of the major challenges in gene therapy is the lack of transcriptional 
control of exogenously introduced genes.  Thus, creating molecular switch systems with 
the ability to regulate target genes through activation by a small molecule should provide 
a pathway for controlling gene expression. One potential target gene is the homeobox 
gene HOXB4, which has been shown to repopulate hematopoietic stem cells in mice, and 
potentially could be used to treat patients with immune deficiency disorders [1-3]. 
OLRP were designed and created using nuclear receptors by taking advantage of the 
modular structure of these receptors and their function in gene regulation. As ligand-
activated transcription factors, these receptors serve as regulators of transcription in 
various cells, regulating metabolic and physiological processes.  Previous work had 
manipulated the structure of these modular proteins by developing variants capable of 
activating in response to the synthetic ligand LG335 rather than the natural ligand 9-cis 
retinoic acid (9cRA).  These constructs were then further modified to contain a Gal4 
DNA binding domain (DBD) fused to either the RXR variant 130 (I268A, I310A, F313A, 
and L436F) ligand binding domain (LBD) (also known as GR130) or the RXR variant 
QCIMFI (Q275C, I310M, and F313I) LBD (also known as GRQCIMFI).  Gal4 is a yeast 
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transcription factor that binds Gal4 RE, a sequence not presence in mammalian cells. 
Both molecular switches are able to bind Gal4 RE in response to LG335 and activate 
expression of a reporter gene in either a two- or one-component system. The two-
component system has the molecular switch on one plasmid, and the artificial promoter 
and reporter gene on a separate plasmid. While the one-component system contains all 
system components on a single plasmid. When characterizing the GR130 variant in the 
two-component system, orthogonal characteristics were observed since no activation 
occurred with the natural ligand 9cRA, and activation occurs in response to the synthetic 
ligand LG335. This variant displayed a 19±5-fold activation and a 50 nM EC50 value in 
the presence of LG335. When GR130 was tested in the one-component system with the 
luciferase gene, reduced luciferase activity was observed in the presence of LG335, 
displaying a 2-fold increase in the EC50 value (100 nM) compared to the two-component 
system, and a lower fold activation of 3±1-fold. The data with the green fluorescent 
protein (GFP) in the one-component system, where the reporter gene was switched from 
luciferase to GFP, was inconclusive, as the sequence of the variant tested was not 
confirmed to be GR130. GR130 displayed insufficient gene expression in the one-
component system with the luciferase reporter gene and was not successfully 
characterized with the GFP reporter gene. Therefore GRQCIMFI was selected as the 
appropriate variant to use as this variant was characterized in both the two- and one-
component systems.  
When the GRQCIMFI variant was evaluated in the two-component system, activation 
was observed in the presence of LG335 with a 10 nM EC50 value and a 6±2-fold 
induction, and 9cRA induced activation only at the highest concentration. A comparable 
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fold induction was observed when the GRQCIMFI variant was cloned into the one-
component system, displaying a 6±1-fold induction but a higher EC50 value of 270 nM.  
The GRQCIMFI variant was also characterized in a transient transfection with a one-
component system containing the reporter gene GFP, and showed green fluorescence in 
30% of the cells in the presence of 10 µM LG335. The one-component system can also 
be introduced virally into NIH3T3 cells, and 30% of the cells were able to stably express 
GFP in the presence of 10 µM LG335. However, the fluorescence intensity was 
significantly decreased in the cells stably transduced with retrovirus in comparison to 
cells that were transiently transfected. 
A comparison of the two variants revealed advantages and disadvantages for each 
molecular switch. The GR130 variant is not activated by the natural ligand 9cRA; 
therefore this variant should not influence endogenous pathways. This variant also 
displays a higher fold induction when compared to the GRQCIMFI variant in the two-
component system. The GR130 variant displays a 19±5-fold induction, whereas 
GRQCIMFI displays a 6±2-fold induction. GRQCIMFI is activated at slightly lower 
concentrations of LG335 in the two-component; displaying a 10 nM EC50 value whereas 
the GR130 variant displays a 50 nM EC50 value.  In the one-component system, 
GRQCIMFI exhibits a consistent fold induction of 6±1-fold whereas the fold induction of 
GR130 significantly decreases to 3±1-fold.  
Since GRQCIMFI was more accurately assessed, this variant was further 
characterized to determine whether the criteria for molecular switch systems discussed in 
Chapter 2 were met. The first criterion included the ability to turn on and off transgene 
expression upon the addition of ligand. As was discussed in the section above, 
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GRQCIMFI was able to control gene expression of both the luciferase and GFP reporter 
genes. However, a significant amount of basal expression was observed which lowered 
the fold induction and leaky expression could be problematic if this system is analyzed in 
animal model studies. The molecular switch could be further developed by increasing the 
fold induction, which can be achieved by either lowering the basal activity or increasing 
the amount of activation. Activation of the molecular switch at lower concentrations of 
ligand would also be advantageous as low drug dosages are desirable in gene therapy 
trials. 
One approach taken to improve the fold induction of GRQCIMFI was to add an 
activation domain, a protein domain that is known to stimulate transcription. Several 
molecular switch systems have incorporated an activation domain as a means to improve 
fold induction. In the initial development of the GeneSwitch® system, the VP16 
activation domain was fused to the C-terminus region of this chimeric protein, enhancing 
the activation approximately 50-fold [4]. The most current Rheoswitch® system, which 
consists of two fusion proteins: a hybrid DBD fused to an EcR LBD, and a RXR LBD 
fused to the VP16 activation domain, displays approximately a 10,000-fold induction [5]. 
The VP16 activation domain was fused to the N-terminus region of GRQCIMFI in an 
effort to increase the fold induction. However, the addition of the VP16 created a 
constitutively active protein, since the luciferase gene was expressed regardless of the 
presence of ligand. A constitutively active receptor is ineffective in a molecular switch 
system since the target gene cannot be turned off. 
VP16 is known to be a potent activation domain; therefore, alternate activation 
domains should be assessed with the molecular switch to determine whether a higher fold 
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activation could be achieved. For example, the GeneSwitch® system was optimized by 
replacing the VP16 activation domain with the human p65 activation domain, which 
reduced the basal activity levels and minimized potential immunogenic reactions [6]. 
Several activation domains have been characterized, such as Oct1, Oct2, Sp1, p65, and 
ITF-1, that are able to stimulate transcription [7]. 
Another approach used to enhance the fold-activation and sensitivity of the molecular 
switch incorporated error-prone PCR and chemical complementation to select for new 
variants with increased sensitivity towards LG335. This method produced a successful 
variant, Q275C, I310M, F313I, L455M (QCIMFILM), which displayed a 10-fold 
increase in sensitivity towards LG335 with a 5 nM EC50 value. The additional mutation at 
the L455 position was further examined by assessing the location in the receptor. The 
RXR crystal structure revealed this residue is located outside of the ligand binding pocket 
and on helix 12 (H12), which was interesting since the residue lacks direct contact with 
the ligand but is able to significantly enhance receptor function. The QCIMFILM variant 
should next be characterized in the one-component system to show gene expression also 
takes place at lower levels of LG335. 
The second criterion for a successful molecular switch system examines the 
specificity of the ligand to the molecular switch, and the specificity of the switch to the 
artificial promoter region. This is particularly important for ensuring that the molecular 
switch does not interfere with any endogenous pathways, preventing adverse side effects. 
The ligand or the molecular switch should not activate expression of endogenous genes, 
and conversely endogenous ligands or receptors should not activate expression of the 
target gene in the molecular switch system.  The results presented in this work have 
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successfully shown that the molecular switch presented is specific to the artificial 
promoter region containing the Gal4 RE, since activation was not observed with 
endogenous RXR RE. Conversely, RXRwt is unable to activate genes controlled by the 
Gal4 RE, so endogenous receptors should not activate expression of the target gene in the 
molecular switch.  However, improvements in the specificity of the ligand to the 
molecular switch are needed. The synthetic ligand LG335 is able to activate gene 
expression with the wild-type receptor with a 4±1-fold induction, but the fold induction is 
substantially lower than the 10±3-fold observed with RXRwt and the natural ligand 
9cRA.  The data also shows that 10 μM 9cRA activates GRQCIMFI, which could initiate 
transcription of genes controlled by the molecular switch in gene therapy applications. 
Although the concentration of endogenous 9cRA remains controversial, studies have 
revealed nanomolar concentration of 9cRA in animal models, which is much lower than 
the levels that activate the molecular switch [8, 9]. The effect of endogenous ligands on 
the molecular switch cannot be fully assessed until the molecular switch is characterized 
in an animal model. In the future, new OLRP should be discovered with new ligands to 
avoid the potential inference dilemma.  
Although the specificity of the molecular switch system to the Gal4 response 
elements have been successfully shown, alternative DNA binding domains can also be 
engineered. While the Gal4 DBD does not bind to endogenous sequences, Gal4 is a yeast 
protein that may cause an immunogenic response if introduced in human gene therapy 
applications. The development of a novel DNA binding domain can be pursued by 
engineering zinc finger motifs to bind an exogenous DNA sequence. Several studies have 
constructed novel DBD that can bind unique 18 bp sequences and have the ability to 
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regulate gene expression [10-13]. Creation of an artificial DBD may eliminate 
immunogenic response if introduced in human gene therapy applications. 
One other criteria for a successful molecular switch system looks at whether ligand 
dosage correlates to the expression of the target gene. The addition of ligand should 
rapidly induce target gene expression, while the removal of ligand should rapidly suspend 
target gene expression. When using transient transfections to characterize the ligand time 
course, the molecular switch system shows rapid induction, where activation levels are 
observed 16 hours after the addition of ligand. However, the removal of LG335 shows 
steady decline in transgene expression. The steady decrease to basal levels was expected 
when considering the stability of LG335.  LG335 has a high melting temperature of 250-
252
o
C, therefore rapid decomposition is unlikely in cell culture assays [14]. Since 
transient transfections were used to characterize the ligand time course, the amount of 
time permitted to evaluate the ligand was limited to three and a half days. In the future, 
the ligand time course should be determined upon stable expression of the molecular 
switch system in a given cell line or animal model. Stable expression allows a more 
accurate assessment of the rate of gene expression since transient transfection factors are 
eliminated, such as plasmid retention. This will provide a more comprehensive 
examination of the ligand’s ability to turn on or off gene expression. Also to further 
understand the pharmacology of LG335, in vivo analysis is essential to determine toxicity 
as well as the rate of metabolism of LG335; however, it is assumed that the 
pharmacological properties of this ligand would be very similar to the analog Targretin.  
7.1.2 Future Work 
200 
 
Although a molecular switch system has been characterized that can proficiently 
regulate gene expression, several other approaches could be implemented for further 
improvements in this system. One area of improvement could be the introduction of a 
control to test the efficiency of dual expression in the same vector. In the current 
molecular switch system, the expression of the reporter gene relies on the expression of 
GRQCIMFI as well as the binding of LG335 to GRQCIMFI. This system is functional in 
transient transfections; however, GFP expression is decreased when virally introduced. 
An appropriate control to develop would consist of a constitutively active receptor 
controlling expression of the reporter gene. This control allows the evaluation of maximal 
activation from the inducible system by eliminating the need of a small molecule to turn 
on gene expression. This control can be developed by fusing the Gal4 DBD to the VP16 
activation domain, which is a chimeric protein capable of inducing expression of genes 
controlled by the Gal4 response elements without the addition of ligand. This fusion 
protein would replace GRQCIMFI in the one-component system and could be used for 
comparing inducible gene expression in transient transfection as well as retroviral 
transductions. 
The one-component system is the preferred vector for the molecular switch system, 
since this vector would increase transduction efficiency while confining all components 
to one segment of DNA. However, several issues have arisen when using a vector 
containing multiple components. One of the issues with constructing this retroviral vector 
is determining the proper arrangement of genes when expressing two genes 
simultaneously. Several groups have observed “positional effects” or different expression 
patterns when expressing two genes within the same vector [15, 16]. These groups have 
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observed that the transgene at the 3’ region is expressed in a lower quantity than the 
transgene expressed at the 5’ region [15, 16]. In the current molecular switch system 
(Figure 7.1A), the molecular switch GRQCIMFI is located near the 5’ region and is 
constitutively expressed under the control of a strong promoter. GRQCIMFI can then 
bind the Gal4 RE upon the addition of LG335 and control expression of the reporter 
gene, which is near the 3’ region. Since the reporter gene is downstream in the molecular 
switch system, the decrease in gene expression observed in retrovirally transduced cells 
could result from inefficient gene expression due to positional effects. A possible method 
to increase expression of the reporter gene is to reorder the gene sequence, where the 
Gal4 RE and the reporter gene are cloned downstream from the 5’ region, and a different 
strong promoter and the molecular switch are cloned upstream from the 3’ region (Figure 
7.1B).  
Transcriptional interference may also be the cause of decreased expression of 
downstream transgenes. Transcriptional interference occurs when multiple transgenes 
contained on a single plasmid are controlled by two separate internal promoters [16, 17]. 
Interestingly, the insertion of enhancer sequences, such as termination signaling 
sequences, has also been used as a molecular tool to overcome transcriptional 
interference and is able to elevate expression levels of the downstream transgene [16]. 
For example, the chicken insulator sequence (cHS4) has been inserted into the Tet-On 
system to improve expression of the target gene [18]. Inserting insulator sequence(s) 
between the reporter gene and molecular switch, as shown in Figure 7.1B, could further 









Figure 7.1: Improvements in molecular switch system: (A) Diagram of the current 
molecular switch system. (B) Diagram of a proposed new molecule switch system that 
would possible enhance gene expression of the reporter gene. 
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Another possible approach to improve gene expression in the molecular switch 
system is to use an alternate viral vector to stably transduce cells and express both the 
molecular switch and the reporter gene. Gene silencing is known to take place in 
retroviral systems due to methylation of viral promoter regions, which may be the cause 
of reduced gene expression with the reporter gene in the current molecular switch system 
[19]. A solution to this problem could be the utilization of a lentiviral system rather than 
a retroviral system. Lentiviruses are RNA viruses within the Retroviridae family; 
therefore, this viral system has the same advantages as retroviruses. In addition, this viral 
system is able to infect both dividing and nondividing cells whereas retroviruses only 
infect nondividing cells. The lentiviral system has successfully transduced a variety of 
cell types, such as mice, rats, chickens, and monkeys without stimulating complete gene 
silencing, where as retroviruses have been only successful in tranducing specific strains 
of mice [20]. Therefore, lentiviral systems offer an alternative method to create cell lines 
that stably express the molecular switch system. This viral system can also be used when 
characterizing the molecular switch system in small and large animal model studies.  
 
7.2  The L455 Project 
7.2.1 Conclusions 
Chapter 6 examined the significance of the L455 position and the effect this 
residue exerts on RXR activity. First, the L455 position was mutated to several amino 
acids to analyze the tolerance at this position. Hydrophobic and polar residues that are 
similar in volume to leucine displayed activation profiles comparable to RXRwt.  The 
L455 variants were then analyzed with various L436 mutations to determine whether one 
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of the L455 mutations could compensate for a nonfunctional variant. Results showed that 
the L436V L455M mutation could restore receptor activity, especially with LG335. 
Lastly, the interactions between L455 variants and the coactivators ACTR and SRC-1 
indicated that perhaps the L455 residue is able to impact the interaction between the 
receptor and the coactivator.  
Previous studies have focused primarily on mutating residues that line the binding 
pocket in order to enhance receptor function. However, this research provides a 
significant contribution in regards to protein engineering as this work reveals the 
capability of mutations outside of the ligand binding pocket to enhance protein function. 
The L455M variant, a residue on H12, was able to enhance receptor activation, 
compensate for a nonfunctional variant, as well as influence coactivator association.  
Applications of this study can lead to further comprehension of the role of nuclear 
receptors in transcriptional regulation.  
7.2.2 Future Work 
To further develop a comprehensive and holistic understanding of the role of L455 in 
receptor function, future work should be conducted to confirm the results previous 
observed. The testing of the single and double variants with other coactivators should be 
performed, which could aid in the identification of the dominant coactivator associated 
with RXR and also facilitate understanding of gene regulation in a specific cell type. 
These variants could also be tested in chemical complementation with corepressors fused 
to the Gal4 activation domain in order to understand corepressor association, since 
nuclear receptors are known to interact with both coactivators and corepressors. Most 
importantly, in vitro binding studies should also be performed with coactivator peptides 
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and the L455M variant, to confirm the stronger interaction observed between L455M and 
the SRC-1 coactivator. Residues analogous to this position in other nuclear receptors 
should be tested to determine whether mutations at this position can affect coactivator 
preference. Receptors having similar activity can perhaps provide some evolutionarily 
insight into the possible role of residues in helix 12 influencing coactivator association.  
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